+

WO1999004026A2 - Vecteurs lentiviraux - Google Patents

Vecteurs lentiviraux Download PDF

Info

Publication number
WO1999004026A2
WO1999004026A2 PCT/US1998/014996 US9814996W WO9904026A2 WO 1999004026 A2 WO1999004026 A2 WO 1999004026A2 US 9814996 W US9814996 W US 9814996W WO 9904026 A2 WO9904026 A2 WO 9904026A2
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
gene
cells
lentiviral vector
expression
Prior art date
Application number
PCT/US1998/014996
Other languages
English (en)
Other versions
WO1999004026A3 (fr
Inventor
Shin-Tai Chen
Mehdi Gasmi
Jiing Kuan Yee
Douglas J. Jolly
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Priority to AU85762/98A priority Critical patent/AU8576298A/en
Priority to EP98936923A priority patent/EP1003894A2/fr
Priority to JP2000503232A priority patent/JP2001510053A/ja
Priority to CA002296319A priority patent/CA2296319A1/fr
Publication of WO1999004026A2 publication Critical patent/WO1999004026A2/fr
Publication of WO1999004026A3 publication Critical patent/WO1999004026A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Definitions

  • the present invention relates generally to pharmaceutical compositions and methods, and more particularly, to lentiviral vectors which are suitable for a wide variety of gene therapy applications.
  • recombinant retroviral gene delivery methods have been most extensively utilized, in part due to: (1) the efficient entry of genetic material (the vector genome) into cells; (2) an active, efficient process of entry into the target cell nucleus; (3) relatively high levels of gene expression; (4) the potential to target particular cellular subtypes through control of the vector-target cell binding and the tissue-specific control of gene expression; (5) a general lack of pre-existing host immunity; and (6) substantial knowledge and clinical experience which has been gained with such vectors.
  • retroviruses are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate.
  • the retroviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each retrovirus.
  • the viral DNA is then integrated pseudo-randomly into the host cell genome of the infecting cell, forming a "provirus" which is inherited by daughter cells.
  • MLV murine leukemia virus
  • One type of retrovirus has been widely utilized for gene therapy applications (see generally Mann et al. (Cell 35:153, 1983), Cane and Mulligan (Proc. Nat'l. Acad. Sci. USA 57:6349, 1984), and Miller et al., Human Gene Therapy 7:5-14,1990.
  • MLV-based vectors One major disadvantage of MLV-based vectors, however, is that the host range (i.e., cells infected with the vector) is limited, and the frequency of transduction of non-replicating cells is generally low.
  • the present invention provides improved lentiviral based vectors and packaging cell lines. The invention also provides other, related, advantages.
  • lentiviral vectors comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, a promoter operably linked to one or more genes of interest, an origin of second strand DNA synthesis and a 3' lentiviral LTR, wherein the lentiviral vector contains a nuclear transport element.
  • the nuclear transport element may be located either upstream (5') or downsteam (3') of the gene of interest.
  • the nuclear transport element is not RRE.
  • the packaging signal is an extended packaging signal.
  • the promoter is a tissue specific promoter, or, alternatively, a promoter such as CMV.
  • the lentiviral vector further comprises an internal ribosome entry site.
  • the lentiviral vector expresses a gene of interest (e.g., a heterologous sequence, although, within certain embodiments lentivirus sequences such as HIV env may also be expressed).
  • suitable genes of interest include cytokines, insulin, ⁇ -gal, alkaline phosphatase (e.g., placental alkaline phosphatase), green fluorescence protein, factor VIII, factor IX, LDL receptor, human growth hormone, EPO, TPO, prodrug activating enzymes, trans- dominant negative viral or cancer-associated proteins, and tyrosine hydroxylase.
  • lentiviruses may be utilized within the context of the present invention, including for example, lentiviruses selected from the group consisting of HIV, HIV-1 , HIV-2 and SIV.
  • expression cassettes are provided.
  • gag/pol expression cassettes comprising a promoter and a sequence encoding gag/pol and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to gag/pol and vpr, vpu, nef or vif.
  • tat expression cassettes are provided comprising a promoter and a sequence encoding tat and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to tat and vpr, vpu, nef or vif.
  • rev expression cassettes comprising a promoter and a sequence encoding rev and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to rev and vpr, vpu, nef or vif.
  • VSV-G expression cassettes are provided comprising a promoter and a sequence encoding VSV-G and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to VSV-G and vpr, vpu, nef or vif.
  • host cells e.g., packaging cell lines
  • packaging cell line comprising an expression cassette that comprises a sequence encoding gag/pol, and a nuclear transport element, wherein the promoter is operably linked to the sequence encoding gag/pol.
  • packaging cell lines comprising a promoter and a sequence encoding tat, rev, or an envelope (e.g., VSV-G), wherein the promoter is operably linked to the sequence encoding tat, rev, or, the envelope.
  • the packaging cell line may further comprise a sequence encoding any one or more of nef, vif, vpu or vpr.
  • the expression cassette is stably integrated.
  • the packaging cell line upon introduction of a lentiviral vector, produces particles at a concentration of greater than 10' cfu/ml.
  • the promoter is inducible.
  • the packaging cell line upon introduction of a lentiviral vector, produces particles that are free of replication competent virus.
  • packaging cell lines comprising an expression cassette which directs the expression of a gag/pol gene, an expression cassette which directs the expression of an env gene (e.g., VSV-G, or an amphotrophic envelope), an expression cassette which directs the expression of Tat, and expression cassette which directs the expression of Rev.
  • a lentiviral vector is introduced into the packaging cell line to produce a vector producing cell line.
  • methods are provided for enhancing production of infectious virus, comprising the step of infecting packaging cell lines with a viral vector, wherein a butyrate salt (e.g., sodium butyrate or potassium butyrate) is added subsequent to, or after infection of the packaging cell line.
  • a butyrate salt e.g., sodium butyrate or potassium butyrate
  • the butyrate salt is added prior to the step of harvesting infectious virus.
  • Figure 1 is a schematic illustration of one representative HIV-1 based vector.
  • Figures 2A, 2B and 2C are schematic illustrations of pCMV-HIV-1, pV653CMV- ⁇ gal, and pCMU-G, respectively.
  • Figures 3A, 3B, 3C and 3D are schematic illustrations of pCH-GP-1, pCH-GP-2, pCH-GP-3 and pCH-GP-4, respectively.
  • Figures 4A and 4B are schematic illustrations of pCMV-tat and pTetO- rev.
  • Figure 5 is a flow chart of one representative method for packaging cell line generation.
  • Figure 6 is a schematic illustration which shows a comparison of the genome organizations of lenti- and oncoretroviruses.
  • Figure 7 is a table which shows the affected HIV-1 accessory proteins on vector production.
  • Figure 8 is a table which shows the expression level of p24 in pCHGP transfected cells.
  • Figure 9 is a bar graph which shows stimulation of vector production by sodium butyrate.
  • vectors derived from either pCMV-HIV-1 (closed boxes) or PCHGP-2 (striped boxes) were generated in 293T cells in the presence of various concentrations of sodium butyrate as indicated.
  • Titers were determined in HT1080 cells as described in materials and methods. Values are the ratios of titers with sodium butyrate over titers without sodium butyrate for each vector.
  • Figure 10 is a bar graph which shows transduction efficiency in HeLa cells. Briefly, 300 ⁇ l of different viral preparations were used to transduce actively- dividing or growth-arrested HeLa cells in 12 well plates. The cells were harvested two days after transduction and the total ⁇ -galactosidase activity was determined by blue cell count after X-Gal staining. The results are presented as a percentage value of vector titer observed in HT1080 cells for each viral preparation ([Titer in HeLa (dividing or quiescent)/Titer in HT1080] X 100).
  • Figure 11 is a bar graph which shows the transduction efficiency in human skin fibroblasts. Briefly, 10 ⁇ l of different types were used to infect dividing and quiescent fibroblast in a 12 well plate. Two days after transduction, titer was determined by blue cell counting after X-Gal staining. Data for transduction of quiescent and dividing fibroblasts, are presented as a percentage value of titer observed in growing HT1080 for each viral preparation ([Titer in fibroblasts (growing or quiescent)/Titer in HT1080] X 100). The values are an average of four experiments.
  • Vector construct refers to a nucleic acid construct which carries, and within certain embodiments, is capable of directing the expression of a nucleic acid molecule of interest.
  • the lentiviral vector must include at least one transcriptional promoter/enhancer or locus defining element(s), or other elements which control gene expression by other means such as alternate splicing, nuclear RNA export, post-translational modification of messenger, or post-transcriptional modification of protein.
  • Such vector constructs must also include a packaging signal, long terminal repeats (LTRs) or portion thereof, and positive and negative strand primer binding sites appropriate to the retrovirus used (if these are not already present in the retroviral vector).
  • LTRs long terminal repeats
  • the recombinant lentiviral vector may also include a signal which directs polyadenylation, selectable markers such as Neo, TK, hygromycin, phleomycin, histidinol, or DHFR, as well as one or more restriction sites and a translation termination sequence.
  • selectable markers such as Neo, TK, hygromycin, phleomycin, histidinol, or DHFR
  • such vectors typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second strand DNA synthesis, and a 3' LTR or a portion thereof.
  • Lentiviral vector particle refers to a lentivirus which carries at least one gene of interest.
  • the retrovirus may also contain a selectable marker.
  • the recombinant lentivirus is capable of reverse transcribing its genetic material into DNA and incorporating this genetic material into a host cell's DNA upon infection.
  • Lentiviral vector particles may have a lentiviral envelope, a non-lentiviral envelope (e.g., an ampho or VSV-G envelope), or a chimeric envelope.
  • Nucleic acid expression vector or “Expression cassette” refers to an assembly which is capable of directing the expression of a sequence or gene of interest.
  • the nucleic acid expression vector must include a promoter which, when transcribed, is operably linked to the sequence(s) or gene(s) of interest, as well as a polyadenylation sequence.
  • the nucleic acid expression vectors described herein may be contained within a plasmid construct.
  • the plasmid construct may also include a bacterial origin of replication, one or more selectable markers, a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a Ml 3 origin of replication), a multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adeno virus origin of replication).
  • a bacterial origin of replication e.g., a Ml 3 origin of replication
  • a signal which allows the plasmid construct to exist as single-stranded DNA e.g., a Ml 3 origin of replication
  • a multiple cloning site e.g., a multiple cloning site
  • a "mammalian" origin of replication e.g., a SV40 or adeno virus origin of replication
  • Packaging cell refers to a cell which contains those elements necessary for production of infectious recombinant retrovirus which are lacking in a recombinant retroviral vector.
  • packaging cells typically contain one or more expression cassettes which are capable of expressing proteins which encode gag, pol and env proteins.
  • Producer cell or “Vector producing cell” refers to a cell which contains all elements necessary for production of recombinant retroviral vector particles.
  • Lentiviral vectors which are designed to carry or express a selected gene(s) or sequence(s) of interest.
  • Lentiviral vectors may be readily constructed from a wide variety of lentiviruses (see RNA Tumor Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985).
  • Representative examples of lentiviruses included HIV, HIV-1 , HIV-2 and SIV.
  • Such lentiviruses may either be obtained from patient isolates, or, more preferably, from depositories or collections such as the American Type Culture Collection (ATCC, Rockville, MD), or isolated from known sources using commonly available techniques.
  • any of the above lentiviruses may be readily utilized in order to assemble or construct lentiviral gene delivery vehicles given the disclosure provided herein, and standard recombinant techniques [e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkle, PNAS 52:488, 1985).
  • portions of the lentiviral gene delivery vehicles may be derived from different viruses.
  • recombinant lentiviral vector LTRs may be derived from an HIV, a packaging signal from SIV, and an origin of second strand synthesis from HIV-2.
  • lentiviral vector constructs comprising a 5' lentiviral LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein said lentiviral vector contains a nuclear transport element that is not RRE.
  • LTRs Long Terminal Repeats
  • U5 Long Terminal Repeats
  • U3 Three elements, designated U5, R and U3.
  • These elements contain a variety of signals which are responsible for the biological activity of a retrovirus, including for example, promoter and enhancer elements which are located within U3.
  • LTRs may be readily identified in the provirus (integrated DNA form) due to their precise duplication at either end of the genome.
  • a 5' LTR should be understood to include a 5' promoter element and sufficient LTR sequence to allow reverse transcription and integration of the DNA form of the vector.
  • the 3' LTR should be understood to include a polyadenylation signal, and sufficient LTR sequence to allow reverse transcription and integration of the DNA form of the vector.
  • the tRNA binding site and origin of second strand DNA synthesis are also important for a retrovirus to be biologically active, and may be readily identified by one of skill in the art.
  • retroviral tRNA binds to a tRNA binding site by Watson-Crick base pairing, and is carried with the retrovirus genome into a viral particle.
  • the tRNA is then utilized as a primer for DNA synthesis by reverse transcriptase.
  • the tRNA binding site may be readily identified based upon its location just downstream from the 5' LTR.
  • the origin of second strand DNA synthesis is, as its name implies, important for the second strand DNA synthesis of a retrovirus. This region, which is also referred to as the poly-purine tract, is located just upstream of the 3' LTR.
  • certain preferred recombinant retroviral vector constructs which are provided herein also comprise a packaging signal, as well as one or more genes of interest, each of which is discussed in more detail below.
  • the lentiviral vectors have a nuclear transport element which, in preferred embodiments is not RRE.
  • suitable nuclear transport elements include the element in Rous sarcoma virus (Ogert, et al., J. Virol.
  • Rous sarcoma virus Rous sarcoma virus
  • Rous sarcoma virus Rous sarcoma virus
  • simian retrovirus type 1 Zalotukhin, et al, J. Virol. 68, 7944-7952, 1994.
  • Other potential elements include the elements in the histone gene (Kedes, Annu. Rev. Biochem.
  • recombinant lentiviral vector constructs which lack both gag/pol and env coding sequences.
  • the phrase "lacks gag/pol or env coding sequences" should be understood to mean that the recombinant lentiviral vector does not contain at least 20, preferably at least 15, more preferably at least 10, and most preferably at least 8 consecutive nucleotides which are found in gag/pol or env genes, and in particular, within gag/pol or env expression cassettes that are used to construct packaging cell lines for the recombinant retroviral vector constructs are set forth in more detail below and in Example 1.
  • lentiviral vector constructs which lack gag/pol or env sequences may be accomplished by preparing vector constructs which lack an extended packaging signal.
  • extended packaging signal refers to a sequence of nucleotides beyond the minimum core sequence which is required for packaging, that allows increased viral titer due to enhanced packaging.
  • tissue-specific promoters are utilized to drive expression of one or more genes of interest.
  • lentiviral vector particles of the invention can contain a liver specific promoter to maximize the potential for liver specific expression of the exogenous DNA sequence contained in the vectors.
  • liver specific promoters include the hepatitis B X-gene promoter and the hepatitis B core protein promoter. These liver specific promoters are preferably employed with their respective enhancers.
  • the enhancer element can be linked at either the 5' or the 3' end of the nucleic acid encoding the therapeutic molecule.
  • the hepatitis B X gene promoter and its enhancer can be obtained from the viral genome as a 332 base pair EcoRV-Ncol DNA fragment employing the methods described in Twu, 1987, J. Virol. (57:3448-3453.
  • the hepatitis B core protein promoter can be obtained from the viral genome as a 584 base pair BamHI-Bglll DNA fragment employing the methods described in Gerlach, 1992, Virol 189:59-66. It may be necessary to remove the negative regulatory sequence in the BamHI-Bglll fragment prior to inserting it.
  • Other liver specific promoters include the AFP (alpha fetal protein) gene promoter and the albumin gene promoter, as disclosed in EP Patent Publication 0 415 731 , the -1 antitrypsin gene promoter, as disclosed in Rettenger, 1994, Proc. Natl. Acad. Sci.
  • the fibrinogen gene promoter the APO-A1 (Apolipoprotein Al ) gene promoter, and the promoter genes for liver transference enzymes such as, for example, SGOT, SGPT and - glutamyle transferase. See also PCT Patent Publications WO 90/07936 and WO 91/02805 for a description of the use of liver specific promoters in lentiviral vector particles.
  • the lentiviral vector constructs provided herein may be generated such that more than one gene of interest is expressed. This may be accomplished through the use of di- or oligo-cistronic cassettes (e.g., where the coding regions are separated by 80 nucleotides or less, see generally Levin et al., Gene 108:161-114, 1991), or through the use of Internal Ribosome Entry Sites ("IRES").
  • IRS Internal Ribosome Entry Sites
  • Packaging cell lines suitable for use with the above described recombinant retroviral vector constructs may be readily prepared given the disclosure provided herein. Briefly, the parent cell line from which the packaging cell line is derived can be selected from a wide variety of mammalian cell lines, including for example, human cells, monkey cells, dog cells, mouse cells, and the like.
  • potential packaging cell line candidates are screened by isolating the human placental alkaline phosphatase (PLAP) gene from pBAAP, and inserting the gene into pNL4-3.
  • PLAP placental alkaline phosphatase
  • the construct is co-transfected with pCMV-G into 293 cells, and the virus harvested 48 hurs after transfection.
  • the resulting virus can be utilized to infect candidate host cells (e.g.,, human cells such as HeLa, HY1080, 293, Jurkats, supTl and CEM), which are subsequently sourted using antibodies specific for PLAP.
  • Production of p24 and reverse transcriptase can also be analyzed in the assessment of suitable packaging cell lines.
  • one or more expression cassettes are introduced into the cell line in order to complement or supply in trans components of the vector which have been deleted (see generally U.S. Serial No. 08/240,030, filed May 9, 1994; see also U.S. Serial No. 07/800,921, filed November 27, 1991).
  • suitable expression cassettes include gag/pol expression cassettes which comprise a promoter and a sequence encoding gag/pol and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to gag/pol and vpr, vpu, nef or vif.
  • tat expression cassettes are provided comprising a promoter and a sequence encoding tat and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to tat and vpr, vpu, nef or vif.
  • rev expression cassettes comprising a promoter and a sequence encoding rev and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to rev and vpr, vpu, nef or vif.
  • VSV-G expression cassettes are provided comprising a promoter and a sequence encoding VSV-G and at least one of vpr, vpu, nef or vif, wherein the promoter is operably linked to VSV-G and vpr, vpu, nef or vif. Utilizing the above-described expression cassettes, a wide variety of packaging cell lines can be generated.
  • packaging cell line comprising an expression cassette that comprises a sequence encoding gag/pol, and a nuclear transport element, wherein the promoter is operably linked to the sequence encoding gag/pol.
  • packaging cell lines comprising a promoter and a sequence encoding tat, rev, or an envelope (e.g., VSV-G), wherein the promoter is operably linked to the sequence encoding tat, rev, or, the envelope.
  • the packaging cell line may further comprise a sequence encoding any one or more of nef, vif, vpu or vpr.
  • the packaging cell line may contain only nef, vif, vpu, or vpr alone, nef and vif, nef and vpu, nef and vpr, vif and vpu, vif and vpr, vpu and vpr, nef vif and vpu, nef vif and vpr, nef vpu and vpr, vvir vpu and vpr, or, all four of nef vif vpu and vpr.
  • the expression cassette is stably integrated.
  • the packaging cell line upon introduction of a lentiviral vector, produces particles at a concentration of greater than 10 5 ,10 6 , 10 7 , 10 8 , or, 10 9 cfu/ml.
  • the promoter is inducible.
  • the packaging cell line upon introduction of a lentiviral vector, produces particles that are free of replication competent virus.
  • pathogenic agent refers to a cell that is responsible for a disease state.
  • pathogenic agents include tumor cells, autoreactive immune cells, hormone secreting cells, cells which lack a function that they would normally have, cells that have an additional inappropriate gene expression which does not normally occur in that cell type, and cells infected with bacteria, viruses, or other intracellular parasites.
  • pathogenic agent may also refer to a cell that has become tumorigenic due to inappropriate insertion of nucleic acid molecules contained by the lentiviral vector into a host cell's genome.
  • nucleic acid molecules which may be carried and/or expressed by lentiviral vector particles of the present invention include genes and other nucleic acid molecules which encode a substance, as well as biologically active nucleic acid molecules such as inactivating sequences that incorporate into a specified intracellular nucleic acid molecule and inactivate that molecule.
  • a nucleic acid molecule is considered to be biologically active when the molecule itself provides the desired benefit.
  • the biologically active nucleic acid molecule may be an inactivating sequence that incorporates into a specified intracellular nucleic acid molecule and inactivates that molecule, or the molecule may be a tRNA, rRNA or mRNA that has a configuration that provides a binding capability.
  • Substances which may be encoded by the nucleic acid molecules described herein include proteins (e.g., antibodies including single chain molecules), immunostimulatory molecules (such as antigens) immunosuppressive molecules, blocking agents, palliatives (such as toxins, antisense ribonucleic acids, ribozymes, enzymes, and other material capable of inhibiting a function of a pathogenic agent) cytokines, various polypeptides or peptide hormones, their agonists or antagonists, where these hormones can be derived from tissues such as the pituitary, hypothalamus, kidney, endothelial cells, liver, pancreas, bone, hemopoetic marrow, and adrenal.
  • proteins e.g., antibodies including single chain molecules
  • immunostimulatory molecules such as antigens
  • immunosuppressive molecules blocking agents
  • palliatives such as toxins, antisense ribonucleic acids, ribozymes, enzymes, and other material capable of inhibiting a
  • Such polypeptides can be used for induction of growth, regression of tissue, suppression of immune responses, apoptosis, gene expression, blocking receptor-ligand interaction, immune responses and can be treatment for certain anemias, diabetes, infections, high blood pressure, abnormal blood chemistry or chemistries (e.g., elevated blood cholesterol, deficiency of blood clotting factors, elevated LDL with lowered HDL), levels of Alzheimer associated amyloid protein, bone erosion/calcium deposition, and controlling levels of various metabolites such as steroid hormones, purines, and pyrimidines.
  • the palliative when "capable of inhibiting a function" is utilized within the context of the present invention, it should be understood that the palliative either directly inhibits the function or indirectly does so, for example, by converting an agent present in the cells from one which would not normally inhibit a function of the pathogenic agent to one which does.
  • functions for viral diseases include adsorption, replication, gene expression, assembly, and exit of the virus from infected cells.
  • functions for cancerous diseases include cell replication, susceptibility to external signals (e.g., contact inhibition), and lack of production of anti-oncogene proteins.
  • cardiovascular disease examples include inappropriate growth or accumulation of material in blood vessels, high blood pressure, undesirable blood levels of factors such as cholesterol or low density lipoprotein that predispose to disease, localized hypoxia, and inappropriately high and tissue-damaging levels of free radicals.
  • functions for neurological conditions include pain, lack of dopamine production, inability to replace damaged cells, deficiencies in motor control of physical activity, inappropriately low levels of various peptide hormones derived from neurological tissue such as the pituitary or hypothalamus, accumulation of Alzheimer's Disease associated amyloid plaque protein, and inability to regenerate damaged nerve junctions.
  • autoimmune or inflammatory diseases include inappropriate production of cytokines and lymphokines, inappropriate production and existence of autoimmune antibodies and cellular immune responses, inappropriate disruption of tissues by proteases and collagenases, lack of production of factors normally supplied by destroyed cells, and excessive or aberrant regrowth of tissues under autoimmune attack.
  • a recombinant lentivirus which directs the expression of a palliative.
  • palliatives that act directly to inhibit the growth of cells include toxins such as ricin (Lamb et al., Eur. J. Biochem. 148:265-210, 1985), abrin (Wood et al., Eur. J. Biochem. 795:723-732, 1991 ; Evensen et al., J. of Biol. Chem. 2(5(5:6848-6852, 1991 ; Collins et al., J. of Biol. Chem. 2(55:8665-8669, 1990; Chen et al., Fed.
  • the lentiviral vector carries a gene specifying a product which is not in itself toxic, but when processed or modified by a protein, such as a protease specific to a viral or other pathogen, is converted into a toxic form.
  • a protein such as a protease specific to a viral or other pathogen
  • recombinant retrovirus could carry a gene encoding a proprotein chain, which becomes toxic upon processing by the HIV protease.
  • a synthetic inactive proprotein form of the toxic ricin or diphtheria A chains could be cleaved to the active form by arranging for the HIV virally encoded protease to recognize and cleave off an appropriate "pro" element.
  • lentiviral vectors which direct the expression of a gene product(s) that activates a compound with little or no cytotoxicity into a toxic product.
  • a gene product(s) that activates a compound with little or no cytotoxicity into a toxic product.
  • gene products which either directly or indirectly activate a compound with little or no cytotoxicity into a toxic product may be utilized within the context of the present invention.
  • Representative examples of such gene products include HSVTK and VZVTK which selectively monophosphorylate certain purine arabinosides and substituted pyrimidine compounds, converting them to cytotoxic or cytostatic metabolites.
  • ganciclovir e.g., FIAC, DHPG
  • HSVTK phosphorylates the drug into its corresponding active nucleotide triphosphate form.
  • the lentiviral vector directs the expression of the herpes simplex virus thymidine kinase ("HSVTK”) gene downstream, and under the transcripfional control of an HIV promoter (which is known to be transcriptionally silent except when activated by HIV tat protein).
  • HSVTK herpes simplex virus thymidine kinase
  • expression of the tat gene product in human cells infected with HIV and carrying the recombinant retrovirus causes increased production of HSVTK.
  • the cells are then exposed to a drug such as ganciclovir, acyclovir or its analogues (FIAC, DHPG).
  • these drugs are known to be phosphorylated by HSVTK (but not by cellular thymidine kinase) to their corresponding active nucleotide triphosphate forms.
  • Acyclovir triphosphates inhibit cellular polymerases in general, leading to the specific destruction of cells expressing HSVTK in transgenic mice (see Borrelli et al., Proc. Natl. Acad. Sci. USA 85:1512, 1988).
  • Those cells containing the recombinant retrovirus and expressing HIV tat protein are selectively killed by the presence of a specific dose of these drugs.
  • lentiviral vectors may be generated which carry a gene for phosphorylation, phosphoribosylation, ribosylation, or other metabolism of a purine- or pyrimidine-based drug.
  • genes may have no equivalent in mammalian cells, and might come from organisms such as a virus, bacterium, fungus, or protozoan.
  • Representative examples include: E. coli guanine phosphoribosyl transferase ("gpt”) gene product, which converts thioxanthine into thioxanthine monophosphate (see Besnard et al., Mol. Cell. Biol.
  • alkaline phosphatase which will convert inactive phosphorylated compounds such as mitomycin phosphate and doxorubicin-phosphate to toxic dephosphorylated compounds
  • fungal e.g., Fusarium oxysporum
  • bacterial cytosine deaminase which will convert 5-fluorocytosine to the toxic compound 5-fluorouracil
  • carboxypeptidase G2 which will cleave the glutamic acid from para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid, thereby creating a toxic benzoic acid mustard
  • Penicillin-V amidase which will convert phenoxyacetabide derivatives of doxorubicin and melphalan to toxic compounds.
  • Conditionally lethal gene products of this type have application to many presently known purine- or pyrimidine-based anticancer drugs, which often require intracellular ribosylation or phosphorylation in order to become effective cytotoxic agents.
  • the conditionally lethal gene product could also metabolize a nontoxic drug, which is not a purine or pyrimidine analogue, to a cytotoxic form (see Searle et al., Brit. J. Cancer 55:377-384, 1986).
  • lentiviral vectors may be constructed to take advantage of the fact that mammalian viruses in general tend to have "immediate early" genes, which are necessary for subsequent transcripfional activation of other viral promoter elements. Gene products of this nature are excellent candidates for intracellular signals (or "identifying agents") of viral infection. Thus, conditionally lethal genes transcribed from transcripfional promoter elements that are responsive to such viral "immediate early" gene products could specifically kill cells infected with any particular virus.
  • vectors expressing a conditionally lethal gene product like HSVTK could result in the destruction of cells infected with a variety of different viruses.
  • lentiviral vectors are provided that produce substances such as inhibitor palliatives, that inhibit viral assembly.
  • the recombinant retrovirus codes for defective gag, pol, env or other viral particle proteins or peptides which inhibit in a dominant fashion the assembly of viral particles. Such inhibition occurs because the interaction of normal subunits of the viral particle is disturbed by interaction with the defective subunits.
  • One way of increasing the effectiveness of inhibitory palliatives is to express inhibitory genes, such as viral inhibitory genes, in conjunction with the expression of genes which increase the probability of infection of the resistant cell by the virus in question. The result is a nonproductive "dead-end" event which would compete for productive infection events.
  • a recombinant retrovirus may be administered that inhibits HIV replication (by expressing anti-sense tat, etc., as described above) and also overexpress proteins required for infection, such as CD4.
  • a relatively small number of vector-infected HIV-resistant cells act as a "sink” or "magnet” for multiple nonproductive fusion events with free virus or virally infected cells.
  • lentiviral vectors are provided for the expression substances such as inhibiting peptides or proteins specific for viral protease. Viral protease cleaves the viral gag and gag/pol proteins into a number of smaller peptides.
  • the HIV protease is known to be an aspartyl protease, and these are known to be inhibited by peptides made from amino acids from protein or analogues. Lentiviral vectors that inhibit HIV will express one or multiple fused copies of such peptide inhibitors.
  • lentiviral vectors discussed above should be effective against many virally linked diseases, cancers, or other pathogenic agents.
  • lentiviral vectors which have a therapeutic effect by encoding one or more ribozymes (RNA enzymes) (Haseloff and Gerlach, Nature 334:585, 1989) which will cleave, and hence inactivate, RNA molecules corresponding to a pathogenic function.
  • ribozymes function by recognizing a specific sequence in the target RNA and this sequence is normally 12 to 17 bp, this allows specific recognition of a particular RNA sequence corresponding to a pathogenic state, such as HIV tat, and toxicity is specific to such pathogenic state.
  • suitable ribozymes include hammerhead ribozymes (see Rossi et al, Pharmac.
  • lentiviral vectors comprising a biologically active nucleic acid molecule that is an antisense sequence (an antisense sequence may also be encoded by a nucleic acid sequence and then produced within a host cell via transcription).
  • antisense sequences are designed to bind to RNA transcripts, and thereby prevent cellular synthesis of a particular protein, or prevent use of that RNA sequence by the cell. Representative examples of such sequences include antisense thymidine kinase, antisense dihydrofolate reductase (Maher and Dolnick, Arch. Biochem. & Biophys.
  • the antisense sequence is selected from the group consisting of sequences which encode influenza virus, HIV, HSV, HPV, CMV, and HBV.
  • the antisense sequence may also be an antisense RNA complementary to RNA sequences necessary for pathogenicity.
  • the biologically active nucleic acid molecule may be a sense RNA (or DNA) complementary to RNA sequences necessary for pathogenicity.
  • antisense RNA may be utilized as an anti-tumor agent in order to induce a potent Class I restricted response.
  • high levels of specific antisense sequences are believed to induce the increased expression of interferons (including gamma-interferon), due to the formation of large quantities of double-stranded RNA.
  • the increased expression of gamma interferon boosts the expression of MHC Class I antigens.
  • Preferred antisense sequences for use in this regard include actin RNA, myosin RNA, and histone RNA. Antisense RNA which forms a mismatch with actin RNA is particularly preferred.
  • lentiviral vectors of the invention express a surface protein that is itself therapeutically beneficial.
  • a surface protein that is itself therapeutically beneficial for example, in the particular case of HIV, expression of the human CD4 protein specifically in HIV-infected cells may be beneficial in two ways:
  • CD4/HIV env complex has been implicated as a cause of cell death
  • additional expression of CD4 in the presence of excess HIV-env present in HIV-infected cells leads to more rapid cell death and thus inhibits viral dissemination.
  • This may be particularly applicable to monocytes and macrophages, which act as a reservoir for virus production as a result of their relative refractility to HIV-induced cytotoxicity (which, in turn, is apparently due to the relative lack of CD4 on their cell surfaces).
  • Still further aspects of the present invention relate to lentiviral vectors capable of immunostimulation.
  • the ability to recognize and defend against foreign pathogens is essential to the function of the immune system.
  • the immune system must be capable of distinguishing "self from "nonself (i.e., foreign), so that the defensive mechanisms of the host are directed toward invading entities instead of against host tissues.
  • Cytolytic T lymphocytes are typically induced, or stimulated, by the display of a cell surface recognition structure, such as a processed, pathogen-specific peptide, in conjunction with a MHC class I or class II cell surface protein.
  • Diseases suitable to treatment include viral infections such as influenza virus, respiratory syncytial virus, HPV, HBV, HCV, EBV, HIV, HSV, FeLV, FIV, Hantavirus, HTLV I, HTLV II and CMV, cancers such as melanomas, renal carcinoma, breast cancer, ovarian cancer and other cancers, and heart disease.
  • the invention provides methods for stimulating a specific immune response and/or inhibiting viral spread by using lentiviral vectors that direct the expression of an antigen or modified form thereof in susceptible target cells, wherein the antigen is capable of either (1) initiating an immune response to the viral antigen or (2) preventing the viral spread by occupying cellular receptors required for viral interactions. Expression of the protein may be transient or stable with time.
  • the lentiviral vector is preferably designed to express a modified form of the antigen which will stimulate an immune response and which has reduced pathogenicity relative to the native antigen.
  • This immune response is achieved when cells present antigens in the correct manner, i.e., in the context of the MHC class I and/or II molecules along with accessory molecules such as CD3, ICAM-1 , ICAM-2, LFA-1 , or analogs thereof (e.g., Altmann et al., Nature 555:512, 1989).
  • An immune response can also be achieved by transferring to an appropriate immune cell (such as a T lymphocyte) (a) the gene for the specific T-cell receptor that recognizes the antigen of interest (in the context of an appropriate MHC molecule if necessary), (b) the gene for an immunoglobulin which recognizes the antigen of interest, or (c) the gene for a hybrid of the two which provides a CTL response in the absence of the MHC context.
  • an appropriate immune cell such as a T lymphocyte
  • the gene for the specific T-cell receptor that recognizes the antigen of interest in the context of an appropriate MHC molecule if necessary
  • the gene for an immunoglobulin which recognizes the antigen of interest or
  • the gene for a hybrid of the two which provides a CTL response in the absence of the MHC context.
  • the antigen generated from a recombinant retrovirus may be in a form which will elicit either or both an HLA class I- or class Il-restricted immune response.
  • the antigen is preferably selected from gp 160, gp 120, and g ⁇ 41 , which have been modified to reduce their pathogenicity.
  • the selected antigen is modified to reduce the possibility of syncytia, to avoid expression of epitopes leading to a disease enhancing immune response, to remove immunodominant, but haplotype-specific epitopes or to present several haplotype-specific epitopes, and allow a response capable of eliminating cells infected with most or all strains of HIV.
  • the haplotype-specific epitopes can be further selected to promote the stimulation of an immune response within an animal which is cross-reactive against other strains of HIV.
  • Antigens from other HIV genes or combinations of genes, such as gag, pol, rev, vif, nef, prot, gag/pol, gag prot, etc., may also provide protection in particular cases.
  • HIV is only one example. This approach may be utilized for many virally linked diseases or cancers where a characteristic antigen (which does not need to be a membrane protein) is expressed.
  • a characteristic antigen which does not need to be a membrane protein
  • Representative examples of such "disease- associated" antigens all or portions of various eukaryotic (including for example, parasites), prokaryotic (e.g., bacterial) or viral pathogens.
  • viral pathogens include the Hepatitis B Virus (“HBV”) and Hepatitis C Virus (“HCV"; see U.S. Serial No.
  • substances which are carried and/or expressed by the lentiviral vectors of the present invention may also include "immunomodulatory factors," many of which are set forth above.
  • Immunomodulatory factors refer to factors that, when manufactured by one or more of the cells involved in an immune response, or, which when added exogenously to the cells, causes the immune response to be different in quality or potency from that which would have occurred in the absence of the factor.
  • the factor may also be expressed from a non-recombinant retrovirus derived gene, but the expression is driven or controlled by the recombinant retrovirus.
  • the quality or potency of a response may be measured by a variety of assays known to one of skill in the art including, for example, in vitro assays which measure cellular proliferation (e.g., ⁇ H thymidine uptake), and in vitro cytotoxic assays (e.g., which measure 51 Q- release) (see, Warner et al, AIDS Res. and Human Retroviruses 7:645-655, 1991).
  • Immunomodulatory factors may be active both in vivo and ex vivo. Representative examples of such factors include cytokines, such as IL-1,
  • IL-2 (Karupiah et al., J. Immunology 744:290-298, 1990; Weber et al., J. Exp. Med. 7(5(5:1716-1733, 1987; Gansbacher et al., J. Exp. Med. 772:1217-1224, 1990; U.S. Patent No. 4,738,927), IL-3, IL-4 (Tepper et al., Ce/7 57:503-512, 1989; Golumbek et al., Science 254:713-716, 1991 ; U.S. Patent No. 5,017,691), IL-5, IL-6 (Brakenhof et al., J. Immunol.
  • IL-7 U.S. Patent No. 4,965,195
  • IL-8 IL-9, IL-10, IL-11, IL-12, IL-13 (Cytokine Bulletin, Summer 1994)
  • IL-14 and IL-15 particularly IL-2, IL-4, IL-6, IL-12, and IL-13, alpha interferon (Finter et al., Drugs 42(5):149-165, 1991 ; U.S. Patent No. 4,892,743; U.S. Patent No. 4,966,843; WO 85/02862; Nagata et al., Nature 284:316-320, 1980; Familletti et al., Methods in Enz.
  • Immunomodulatory factors may also be agonists, antagonists, or ligands for these molecules. For example soluble forms of receptors can often behave as antagonists for these types of factors, as can mutated forms of the factors themselves.
  • a known therapeutic effector in chronic hepatitis B infections is alpha interferon. This has been found to be efficacious in compensating a patient's immunological deficit, and thereby assisting recovery from the disease.
  • a suitable immunomodulatory factor may be experimentally determined. Briefly, blood samples are first taken from patients with a hepatic disease.
  • Peripheral blood lymphocytes are restimulated in vitro with autologous or HLA matched cells (e.g., EBV transformed cells) that have been transduced with a recombinant retrovirus which directs the expression of an immunogenic portion of a hepatitis antigen and the immunomodulatory factor.
  • HLA matched cells e.g., EBV transformed cells
  • a recombinant retrovirus which directs the expression of an immunogenic portion of a hepatitis antigen and the immunomodulatory factor.
  • These stimulated PBLs are then used as effectors in a CTL assay with the HLA matched transduced cells as targets.
  • the immunomodulatory factor gamma interferon is particularly preferred.
  • the present invention also includes lentiviral vectors which encode immunogenic portions of desired antigens including, for example, viral, bacterial or parasite antigens.
  • desired antigens including, for example, viral, bacterial or parasite antigens.
  • at least one immunogenic portion of a hepatitis B antigen can be incorporated into a lentiviral vector.
  • the immunogenic portion(s) which are incorporated into the lentiviral vector may be of varying length, although it is generally preferred that the portions be at least 9 amino acids long, and may include the entire antigen. Immunogenicity of a particular sequence is often difficult to predict, although T cell epitopes may be predicted utilizing the HLA A2.1 motif described by Falk et al. (Nature 557:290, 1991).
  • peptides may be synthesized and used as targets in an in vitro cytotoxic assay.
  • Other assays may also be utilized, including, for example, ELIS A which detects the presence of antibodies against the newly introduced vector, as well as assays which test for T helper cells, such as gamma-interferon assays, IL-2 production assays, and proliferation assays.
  • At least one immunogenic portion of a hepatitis C antigen can be incorporated into a lentiviral vector.
  • Preferred immunogenic portion(s) of hepatitis C may be found in the C and NS3-NS4 regions since these regions are the most conserved among various types of hepatitis C virus (Houghton et al., Hepatology 74:381 -388, 1991).
  • Particularly preferred immunogenic portions may be determined by a variety of methods. For example, as noted above for the hepatitis B virus, identification of immunogenic portions of the polypeptide may be predicted based upon amino acid sequence. Briefly, various computer programs which are known to those of ordinary skill in the art may be utilized to predict CTL epitopes.
  • CTL epitopes for the HLA A2.1 haplotype may be predicted utilizing the HLA A2.1 motif described by Falk et al. (Nature 557:290, 1991). From this analysis, peptides are synthesized and used as targets in an in vitro cytotoxic assay.
  • disease-associated antigens which may be carried by the gene delivery constructs of the present invention include, for example immunogenic, non- tumorigenic forms of altered cellular components which are normally associated with tumor cells (see U.S. Serial No. 08/104,424).
  • altered cellular components which are normally associated with tumor cells include ras (wherein is understood to refer to antigens which have been altered to be non- tumorigenic), p53*, Rb , altered protein encoded by Wilms' tumor gene, ubiquitin , mucin, protein encoded by the DCC.
  • APC and MCC genes, as well as receptors or receptor-like structures such as neu, thyroid hormone receptor, Platelet Derived Growth Factor ("PDGF”) receptor, insulin receptor, Epidermal Growth Factor (“EGF”) receptor, and the Colony Stimulating Factor (“CSF”) receptor.
  • PDGF Platelet Derived Growth Factor
  • EGF Epidermal Growth Factor
  • CSF Colony Stimulating Factor
  • Immunogenic portions of the disease-associated antigens described herein may be selected by a variety of methods.
  • the HLA A2A/K transgenic mouse has been shown to be useful as a model for human T-cell recognition of viral antigens.
  • the murine T-cell receptor repertoire recognizes the same antigenic determinants recognized by human T-cells.
  • the CTL response generated in the HLA A2.1/K 0 transgenic mouse is directed toward virtually the same epitope as those recognized by human CTLs of the HLA A2.1 haplotype (Vitiello et al., J. Exp. Med. 775:1007-1015, 1991; Vitiello et al., Abstract of Molecular Biology of Hepatitis B Virus Symposia, 1992).
  • Immunogenic proteins of the present invention may also be manipulated by a variety of methods known in the art, in order to render them more immunogenic.
  • Representative examples of such methods include: adding amino acid sequences that correspond to T helper epitopes; promoting cellular uptake by adding hydrophobic residues; by forming particulate structures; or any combination of these (see generally, Hart, op. cit., Milich et al., Proc. Natl. Acad. Sci. USA 55: 1610-1614, 1988; Willis, Nature 340:323-324, 1989; Griffiths et al., J. Virol. 65:450-456, 1991). Sequences which encode the above-described nucleic acid molecules may be obtained from a variety of sources.
  • plasmids which contain sequences that encode altered cellular products may be obtained from a depository such as the American Type Culture Collection (ATCC, Rockville, Maryland), or from commercial sources such as Advanced Biotechnologies (Columbia, Maryland).
  • ATCC American Type Culture Collection
  • ATCC No. 41000 containing a G to T mutation in the 12th codon of ras
  • ATCC No. 41049 containing a G to A mutation in the 12th codon
  • nucleic acid molecules that encode the above-described substances, as well as other nucleic acid molecules that are advantageous for use within the present invention may be readily obtained from a variety of sources, including for example depositories such as the American Type Culture Collection (ATCC, Rockville, Maryland), or from commercial sources such as British Bio-Technology Limited (Cowley, Oxford England).
  • Representative examples include BBG 12 (containing the GM-CSF gene coding for the mature protein of 127 amino acids), BBG 6 (which contains sequences encoding gamma interferon), ATCC No. 39656 (which contains sequences encoding TNF), ATCC No. 20663 (which contains sequences encoding alpha interferon), ATCC Nos.
  • 31902, 31902 and 39517 (which contains sequences encoding beta interferon), ATCC No 67024 (which contains a sequence which encodes Interleukin-lb), ATCC Nos. 39405, 39452, 39516, 39626 and 39673 (which contains sequences encoding Interleukin-2), ATCC Nos. 59399, 59398, and 67326 (which contain sequences encoding Interleukin-3), ATCC No. 57592 (which contains sequences encoding Interleukin-4), ATCC Nos. 59394 and 59395 (which contain sequences encoding Interleukin-5), and ATCC No. 67153 (which contains sequences encoding Interleukin-6).
  • ATCC No. 45020 contains the total genomic DNA of hepatitis B (extracted from purified Dane particles) (see Figure 3 of Blum et al., TIG 5(5):154-158, 1989) in the BamU I site of pBR322 (Moriarty et al, Proc. Natl. Acad. Sci. USA 75:2606-2610, 1981). (Note that correctable errors occur in the sequence of ATCC No. 45020.)
  • cDNA sequences for use with the present invention may be obtained from cells which express or contain the sequences. Briefly, within one embodiment mRNA from a cell which expresses the gene of interest is reverse transcribed with reverse transcriptase using oligo dT or random primers. The single stranded cDNA may then be amplified by PCR (see U.S. Patent Nos. 4,683,202, 4,683,195 and 4,800,159). See also PCR Technology: Principles and Applications for DNA Amplification, Erlich (ed.), Stockton Press, 1989) utilizing oligonucleotide primers complementary to sequences on either side of desired sequences.
  • a double stranded DNA is denatured by heating in the presence of heat stable Taq polymerase, sequence specific DNA primers, ATP, CTP, GTP and TTP. Double- stranded DNA is produced when synthesis is complete. This cycle may be repeated many times, resulting in a factorial amplification of the desired DNA.
  • Nucleic acid molecules which are carried and/or expressed by the lentiviral vectors described herein may also be synthesized, for example, on an Applied Biosystems Inc. DNA synthesizer (e.g., APB DNA synthesizer model 392 (Foster City, California).
  • the present invention also provides methods for delivering a selected heterologous sequence to a vertebrate or insect, comprising the step of administering to a vertebrate or insect a lentiviral vector particle as described herein which is capable of expressing the selected heterologous sequence.
  • lentiviral vector particles may be administered either directly (e.g., intravenously, intramuscularly, intraperitoneally, subcutaneously, orally, rectally, intraocular ly, intranasally), or by various physical methods such as lipofection (Feigner et al., Proc. Natl. Acad. Sci.
  • the lentiviral vector particles may either be administered directly (i.e., in vivo), or to cells which have been removed (ex vivo), and subsequently returned.
  • lentiviral vector particles may be administered to a vertebrate or insect organism or cell for a wide variety of both therapeutic or productive purposes, including for example, for the purpose of stimulating a specific immune response; inhibiting the interaction of an agent with a host cell receptor; to express a toxic palliative, including for example, conditional toxic palliatives; to immunologically regulate the immune system; to express markers, for replacement gene therapy and/or to produce a recombinant protein.
  • compositions and methods are provided for administering a lentiviral vector particle which is capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous, auto-immune or immune diseases.
  • diseases include viral infections such as HIV, HBV, HCV, HTLV I, HTLV II, CMV, EBV and HPV, melanomas, diabetes, graft vs. host disease, Alzheimer's disease and heart disease.
  • compositions and methods are provided for stimulating an immune response (either humoral or cell-mediated) to a pathogenic agent, such that the pathogenic agent is either killed or inhibited.
  • pathogenic agents include bacteria, fungi, parasites, viruses and cancer cells.
  • the pathogenic agent is a virus
  • methods are provided for stimulating a specific immune response and inhibiting viral spread by using a lentiviral vector particle that directs the expression of an antigen or modified form thereof to susceptible target cells capable of either (1) initiating an immune response to the viral antigen or (2) preventing the viral spread by occupying cellular receptors required for viral interactions.
  • Expression of the vector nucleic acid encoded protein may be transient or stable with time.
  • the lentiviral vector is preferably designed to express a modified form of the antigen which will stimulate an immune response and which has reduced pathogenicity relative to the native antigen.
  • lentiviral vector particles are expected to do this efficiently because they closely mimic genuine viral infection and because they: (a) are able to infect non- replicating cells, (b) do not integrate into the host cell genome, (c) are not associated with any life threatening diseases, and (d) express high levels of heterologous protein. Because of these differences, lentiviral vectors can easily be thought of as safe viral vectors which can be used on healthy individuals for vaccine use.
  • This aspect of the invention has a further advantage over other systems that might be expected to function in a similar manner, in that the presenter cells are fully viable and healthy, and low levels of viral antigens, relative to heterologous genes, are expressed.
  • Such an approach may be extended to the expression of a peptide having multiple epitopes, one or more of the epitopes being derived from different proteins.
  • this aspect of the invention allows efficient stimulation of cytotoxic T lymphocytes (CTL) directed against antigenic epitopes, and peptide fragments of antigens encoded by sub-fragments of genes, through intracellular synthesis and association of these peptide fragments with MHC Class I molecules.
  • CTL cytotoxic T lymphocytes
  • This approach may be utilized to map major immunodominant epitopes for CTL induction.
  • An immune response may also be achieved by transferring to an appropriate immune cell (such as a T lymphocyte) the gene for the specific T cell receptor which recognizes the antigen of interest (in the context of an appropriate MHC molecule if necessary), for an immunoglobulin which recognizes the antigen of interest, or for a hybrid of the two which provides a CTL response in the absence of the MHC context.
  • the lentiviral vector particles may be used as an immunostimulant, immunomodulator, or vaccine.
  • lentiviral vector particles deliver and express defective interfering viral structural proteins, which inhibit viral assembly.
  • Such lentiviral vector particles may encode defective gag, pol, env or other viral particle proteins or peptides and these would inhibit in a dominant fashion the assembly of viral particles. This occurs because the interaction of normal subunits of the viral particle is disturbed by interaction with the defective subunits.
  • methods are provided for the expression of inhibiting peptides or proteins specific for viral protease. Briefly, viral protease cleaves the viral gag and gag/pol proteins into a number of smaller peptides.
  • HIV protease is known to be an aspartyl protease and these are known to be inhibited by peptides made from amino acids from protein or analogues. Lentiviral vectors to inhibit HIV will express one or multiple fused copies of such peptide inhibitors.
  • Another embodiment involves the delivery of suppressor genes which, when deleted, mutated, or not expressed in a cell type, lead to tumorigenesis in that cell type.
  • Reintroduction of the deleted gene by means of a lentiviral vector particle leads to regression of the tumor phenotype in these cells.
  • cancers are retinoblastoma and Wilms Tumor. Since malignancy can be considered to be an inhibition of cellular terminal differentiation compared with cell growth, administration of the lentiviral vector particle and expression of gene products which lead to differentiation of a tumor should also, in general, lead to regression.
  • the lentiviral vector provides a therapeutic effect by transcribing a ribozyme (an RNA enzyme) (Haseloff and Gerlach, Nature 554:585, 1989) which will cleave and hence inactivate RNA molecules corresponding to a pathogenic function. Since ribozymes function by recognizing a specific sequence in the target RNA and this sequence is normally 12 to 17 bp, this allows specific recognition of a particular RNA species such as a RNA or a retroviral genome. Additional specificity may be achieved in some cases by making this a conditional toxic palliative (see below).
  • a ribozyme an RNA enzyme
  • lentiviral vector particles may be delivered which inhibit HIV replication (by expressing anti-sense tat, etc., as described above) and also overexpress proteins required for infection, such as CD4.
  • a relatively small number of vector-infected HIV-resistant cells act as a "sink” or "magnet” for multiple nonproductive fusion events with free virus or virally infected cells.
  • infectious diseases, cancers, autoimmune diseases, and other diseases involve the interaction of viral particles with cells, cells with cells, or cells with factors produced by themselves or other cells.
  • viruses commonly enter cells via receptors on the surface of susceptible cells.
  • cancers or other proliferative conditions e.g., restenosis
  • cells may respond inappropriately or not at all to signals from other cells or factors, or specific factors may be mutated, overexpressed, or underexpressed, resulting in loss of appropriate cell cycle control.
  • autoimmune disease there is inappropriate recognition of "self markers.
  • such interactions may be blocked by producing, in vivo, an analogue to either of the partners in an interaction.
  • cell cycle control may be restored by preventing the transition from one phase to another (e.g., Gl to S phase) using a blocking factor which is absent or underexpressed.
  • This blocking action may occur intracellularly, on the cell membrane, or extracellularly, and the action of the lentivirus vector particle carrying a gene for a blocking agent, can be mediated either from inside a susceptible cell or by secreting a version of the blocking protein to locally block the pathogenic interaction.
  • the two agents of interaction are the gp 120/gp 41 envelope protein and the CD4 receptor molecule.
  • an appropriate blocker would be a lentiviral vector expressing either an HIV env analogue that blocks HIV entry without causing pathogenic effects, or a CD4 receptor analogue.
  • the CD4 analogue would be secreted and would function to protect neighboring cells, while the gp 120/gp 41 is secreted or produced only intracellularly so as to protect only the vector- containing cell. It may be advantageous to add human immunoglobulin heavy chains or other components to CD4 in order to enhance stability or complement lysis.
  • Administration of a lentiviral vector particle encoding such a hybrid-soluble CD4 to a host results in a continuous supply of a stable hybrid molecule. Efficacy of treatment can be assayed by measuring the usual indicators of disease progression, including antibody level, viral antigen production, infectious HIV levels, or levels of nonspecific infections.
  • cell cycle progression may be halted by the expression of a number of different factors that affect signaling by cyclins or cyclin-dependent kinases (CDK).
  • CDK cyclin-dependent kinases
  • the cyclin-dependent kinase inhibitors, pi 6, p21, and p27 each regulate cyclimCDK mediated cell cycle signaling.
  • Overexpression of these factors within a cell by a lentiviral vector particle results in a cytostatic suppression of cell proliferation.
  • Other factors that may be used therapeutically, as blocking agents or targets include, for example, wild-type or mutant Rb, p53, Myc, Fos, Jun, PCNA , GAX, and pl5.
  • lentiviral vector particles which direct the expression of an agent (or "palliative") which is capable of inhibiting a function of a pathogenic agent or gene.
  • agent or "palliative" which is capable of inhibiting a function of a pathogenic agent or gene.
  • "capable of inhibiting a function” means that the palliative either directly inhibits the function or indirectly does so, for example, by converting an agent present in the cells from one which would not normally inhibit a function of the pathogenic agent to one which does.
  • functions for viral diseases include adsorption, replication, gene expression, assembly, and exit of the virus from infected cells.
  • Examples of such functions for a cancerous cell, cancer-promoting growth factor, or uncontrolled proliferative condition include viability, cell replication, altered susceptibility to external signals (e.g., contact inhibition), and lack of production or production of mutated forms of anti-oncogene proteins.
  • the lentiviral vector particle directs the expression of a gene which can interfere with a function of a pathogenic agent, for instance in viral or malignant diseases.
  • a pathogenic agent for instance in viral or malignant diseases.
  • Such expression may either be essentially continuous or in response to the presence in the cell of another agent associated either with the pathogenic condition or with a specific cell type (an "identifying agent").
  • vector delivery may be controlled by targeting vector entry specifically to the desired cell type (for instance, a virally infected or malignant cell) as discussed above.
  • leukophoresis in which about 20% of an individual's PBLs are removed at any one time and manipulated in vitro. Thus, approximately 2 x 10 9 cells may be treated and replaced. Repeat treatments may also be performed. Alternatively, bone marrow may be treated and allowed to amplify the effect as described above.
  • packaging cell lines producing a vector may be directly injected into a subject, allowing continuous production of recombinant virions.
  • lentiviral vector particles which express RNA complementary to key pathogenic gene transcripts for example, a viral gene product or an activated cellular oncogene
  • lentiviral vector particles which express RNA complementary to key pathogenic gene transcripts (for example, a viral gene product or an activated cellular oncogene) can be used to inhibit translation of that transcript into protein, such as the inhibition of translation of the HIV tat protein. Since expression of this protein is essential for viral replication, cells containing the lentiviral vector particle would be resistant to HIV replication.
  • RNA complementary to the viral packaging signal e.g., an HIV packaging signal when the palliative is directed against HIV
  • the association of these molecules with the viral packaging signal will, in the case of retroviruses, inhibit stem loop formation or tRNA primer binding required for proper encapsidation or replication.
  • lentiviral vector particles may be introduced which expresses a palliative capable of selectively inhibiting the expression of a pathogenic gene, or a palliative capable of inhibiting the activity of a protein produced by the pathogenic agent.
  • a mutant tat protein which lacks the ability to transactivate expression from the HIV LTR and interferes (in a transdominant manner) with the normal functioning of tat protein.
  • Such a mutant has been identified for HTLV II tat protein ("XII Leu 5 " mutant; see Wachsman et al., Science 235:614, 1987).
  • a mutant transrepressor tat should inhibit replication much as has been shown for an analogous mutant repressor in HSV-1 (Friedmann et al., Nature 555:452, 1988).
  • transcripfional repressor protein can be selected for in tissue culture using any viral-specific transcripfional promoter whose expression is stimulated by a virus-specific transactivating protein (as described above).
  • a virus-specific transactivating protein as described above.
  • HIV virus-specific transactivating protein
  • a cell line expressing HIV tat protein and the HSVTK gene driven by the HIV promoter will die in the presence of ACV.
  • a mutant with the appropriate properties i.e., represses transcription from the HIV promoter in the presence of wild-type tat
  • the mutant gene can then be reisolated from these cells.
  • a cell line containing multiple copies of the conditionally lethal vector/tat system may be used to assure that surviving cell clones are not caused by endogenous mutations in these genes.
  • a battery of randomly mutagenized tat genes are then introduced into these cells using a "rescuable" lentivirus vector (i.e., one that expresses the mutant tat protein and contains a bacterial origin of replication and drug resistance marker for growth and selection in bacteria). This allows a large number of random mutations to be evaluated and permits facile subsequent molecular cloning of the desired mutant cell line. This procedure may be used to identify and utilize mutations in a variety of viral transcripfional activator/viral promoter systems for potential antiviral therapies.
  • Another approach for inhibiting a pathogenic agent is to express a palliative which is toxic for the cell expressing the pathogenic condition.
  • expression of the palliative from the lentiviral vector should be limited by the presence of an entity associated with the pathogenic agent, such as a specific viral RNA sequence identifying the pathogenic state, in order to avoid destruction of nonpathogenic cells.
  • lentiviral vector particles can be utilized to express a toxic gene (as discussed above) from a cell-specific responsive vector.
  • a toxic gene as discussed above
  • rapidly replicating cells which contain the RNA sequences capable of activating the cell-specific responsive vectors, are preferentially destroyed by the cytotoxic agent produced by the lentiviral vector particle.
  • the lentiviral vector can carry a gene for phosphorylation, phosphoribosylation, ribosylation, or other metabolism of a purine- or pyrimidine-based drug.
  • This gene may have no equivalent in mammalian cells and might come from organisms such as a virus, bacterium, fungus, or protozoan.
  • An example of this would be the E. coli guanine phosphoribosyl transferase gene product, which is lethal in the presence of thioxanthine (see Besnard et al, Mol. Cell. Biol. 7:4139-4141, 1987).
  • Conditionally lethal gene products of this type have application to many presently known purine- or pyrimidine-based anticancer drugs, which often require intracellular ribosylation or phosphorylation in order to become effective cytotoxic agents.
  • the conditionally lethal gene product could also metabolize a nontoxic drug which is not a purine or pyrimidine analogue to a cytotoxic form (see Searle et al., Brit. J. Cancer 55:377-384, 1986).
  • lentiviral vectors which direct the expression of a gene product capable of activating an otherwise inactive precursor into an active inhibitor of the pathogenic agent.
  • the HSVTK gene product may be used to more effectively metabolize potentially antiviral nucleoside analogues such as AZT or ddC.
  • the HSVTK gene may be expressed under the control of a cell-specific responsive vector and introduced into these cell types.
  • AZT and other nucleoside antivirals
  • HSVTK a nucleoside and nucleoside kinase with very broad substrate specificity
  • AZT or ddC therapy will thereby be more effective, allowing lower doses, less generalized toxicity, and higher potency against productive infection.
  • Additional nucleoside analogues whose nucleotide triphosphate forms show selectivity for retroviral reverse transcriptase but, as a result of the substrate specificity of cellular nucleoside and nucleotide kinases are not phosphorylated, will be made more efficacious.
  • lentiviral vector particles to human T cell and macrophage/monocyte cell lines can increase their resistance to HIV in the presence of AZT and ddC compared to the same cells without retroviral vector treatment.
  • Treatment with AZT would be at lower than normal levels to avoid toxic side effects but still efficiently inhibit the spread of HIV. The course of treatment would be as described for the blocker.
  • the lentiviral vector particle carries a gene specifying a product which is not in itself toxic but, when processed or modified by a protein such as a protease specific to a viral or other pathogen, is converted into a toxic form.
  • the lentiviral vector could carry a gene encoding a proprotein for ricin A chain, which becomes toxic upon processing by the HIV protease.
  • a synthetic inactive proprotein form of the toxin ricin or diphtheria A chains could be cleaved to the active form by arranging for the HIV virally encoded protease to recognize and cleave off an appropriate "pro" element.
  • the lentiviral vector particle may express a "reporting product" on the surface of the target cells in response to the presence of an identifying agent in the cells (such as expression of a viral gene).
  • This surface protein can be recognized by a cytotoxic agent, such as antibodies for the reporting protein, or by cytotoxic T cells.
  • a cytotoxic agent such as antibodies for the reporting protein
  • cytotoxic T cells such as antibodies for the reporting protein
  • a detection system see below
  • a surface protein could be expressed which would itself be therapeutically beneficial.
  • expression of the human CD4 protein specifically in HIV-infected cells may be beneficial in two ways:
  • CD4 Binding of CD4 to HIV env intracellularly could inhibit the formation of viable viral particles, much as soluble CD4 has been shown to do for free virus, but without the problem of systematic clearance and possible immunogenicity, since the protein will remain membrane bound and is structurally identical to endogenous CD4 (to which the patient should be immunologically tolerant).
  • CD4/HIV env complex has been implicated as a cause of cell death
  • additional expression of CD4 in the presence of excess H ⁇ V-env present in HIV-infected cells leads to more rapid cell death and thus inhibits viral dissemination.
  • This may be particularly applicable to monocytes and macrophages, which act as a reservoir for virus production as a result of their relative refractility to HIV-induced cytotoxicity (which, in turn, is apparently due to the relative lack of CD4 on their cell surfaces).
  • the lentiviral vector particle can provide a ribozyme which will cleave and inactivate RNA molecules essential for viability of the vector infected cell.
  • a ribozyme which will cleave and inactivate RNA molecules essential for viability of the vector infected cell.
  • the above-described technique of expressing a palliative in a cell in response to a specific RNA sequence can also be modified to enable detection of a particular gene in a cell which expresses an identifying protein (for example, a gene carried by a particular virus), and hence enable detection of cells carrying that virus.
  • this technique enables the detection of viruses (such as HIV) in a clinical sample of cells carrying an identifying protein associated with the virus.
  • This modification can be accomplished by providing a genome coding for a product, the presence of which can be readily identified (the "marker product”), in a lentiviral vector which responds to the presence of the identifying protein in the infected cells.
  • a product the presence of which can be readily identified
  • HIV when it infects suitable cells, makes tat and rev.
  • the indicator cells can thus be provided with a genome (such as by infection with an appropriate lentivirus particle) which codes for a marker gene, such as the alkaline phosphatase gene, ⁇ -galactosidase gene, or the luciferase gene which is expressed by the lentivirus particle upon activation by the tat and/or rev RNA transcript.
  • ⁇ -galactosidase or alkaline phosphatase exposing the cells to substrate analogues results in a color or fluorescence change if the sample is positive for HIV.
  • luciferase exposing the sample to luciferin will result in luminescence if the sample is positive for HIV.
  • the viral titre can be measured directly by counting colored or fluorescent cells, or by making cell extracts and performing a suitable assay.
  • virus titre can also be measured by performing enzyme assays on the cell surface using a fluorescent substrate.
  • Further specificity can be incorporated into the preceding system by testing for the presence of the virus either with or without neutralizing antibodies to that virus. For example, in one portion of the clinical sample being tested, neutralizing antibodies to HIV may be present; whereas in another portion there would be no neutralizing antibodies. If the tests were negative in the system where there were antibodies and positive where there were no antibodies, this would assist in confirming the presence of HIV.
  • the presence of a particular gene may be determined in a cell sample.
  • the cells of the sample are infected with a suitable lentiviral vector particle which carries the reporter gene which is only expressed in the presence of the appropriate viral RNA transcript.
  • the reporter gene after entering the sample cells, will express its reporting product (such as ⁇ -galactosidase or luciferase) only if the host cell expresses the appropriate viral proteins.
  • the present invention also provides lentiviral vector particles capable of suppressing one or more elements of the immune system in target cells infected with the lentivirus.
  • specific down-regulation of inappropriate or unwanted immune responses such as in chronic hepatitis or in transplants of heterologous tissue such as bone marrow, can be engineered using immune-suppressive viral gene products which suppress surface expression of transplantation (MHC) antigen.
  • MHC transplantation
  • Group C adenoviruses Ad2 and Ad5 possess a 19 kd glycoprotein (gp 19) encoded in the E3 region of the virus.
  • This gp 19 molecule binds to class I MHC molecules in the endoplasmic reticulum of cells, and prevents terminal glycosylafion and translocation of class I MHC to the cell surface.
  • donor bone marrow cells may be infected with a gp 19-encoding lentiviral vector which, upon expression of the gp 19, inhibit the surface expression of MHC class I transplantation antigens.
  • These donor cells may be transplanted with low risk of graft rejection and may require a minimal immunosuppressive regimen for the transplant patient. This may allow an acceptable donor-recipient chimeric state to exist with fewer complications.
  • lentiviral vectors may be utilized to directly transduce synoviocytes, either in vivo, ex vivo.
  • An alternative method involves the use of anti-sense message, ribozyme, or other specific gene expression inhibitor specific for T cell clones which are autoreactive in nature. These block the expression of the T cell receptor of particular unwanted clones responsible for an autoimmune response.
  • the anti-sense, ribozyme, or other gene may be introduced using the viral vector delivery system.
  • One further aspect of the present invention relates to transforming cells of a vertebrate or insect with a lentiviral vector which supplies genetic sequences capable of expressing a therapeutic protein.
  • the lentiviral vector is designed to express a therapeutic protein capable of preventing, inhibiting, stabilizing or reversing an inherited or noninherited genetic defect in metabolism, immune regulation, hormonal regulation, enzymatic or membrane associated structural function.
  • This embodiment also describes the lentiviral vector particle capable of transducing individual cells, whereby the therapeutic protein is able to be expressed systemically or locally from a specific cell or tissue, whereby the therapeutic protein is capable of (a) the replacement of an absent or defective cellular protein or enzyme, or (b) supplement production of a defective of low expressed cellular protein or enzyme.
  • Such diseases may include cystic fibrosis, Parkinson's disease, hypercholesterolemia, adenosine deaminase deficiency, ⁇ -globin disorders, Hemophilia A & B, Gaucher's disease, diabetes and leukemia.
  • vectors as described herein are utilized in order to provide long-term expression of the desired gene of interest.
  • Gaucher disease is a genetic disorder that is characterized by the deficiency of the enzyme glucocerebrosidase.
  • This type of therapy is an example of a single gene replacement therapy by providing a functional cellular enzyme.
  • This enzyme deficiency leads to the accumulation of glucocerebroside in the lysosomes of all cells in the body.
  • the disease phenotype is manifested only in the macrophages, except in the very rare neuronpathic forms of the disease. The disease usually leads to enlargement of the liver and spleen and lesions in the bones. (For a review, see Science 256:194, 1992, and 77?e Metabolic Basis of Inherited Disease, 6th ed., Scriver et al., vol. 2, p. 1677).
  • lentiviral vector particles expressing a B-domain deleted factor VIII protein are provided (see also PCT WO
  • the B domain separates the second and third A domains of factor FVIII in the newly synthesized single-chain molecule.
  • the B domain extends from amino acids 712 to 1648 according to Wood et al, 1984, Nature 312:330-337.
  • Proteolytic activation of factor VIIII involves cleavage at specific Arg residues located at positions 372, 740, and 1689. Cleavages of plasma factor VIII by thrombin or Factor Xa at Arg 372 and Arg 1689 are essential for factor VIII to participate in coagulation.
  • activated factor VIII consists of a heterodimer comprising amino acids residues 1-372 (containing the Al domain) and residues 373-740 (containing the A2 domain), and residues 1690-2332 (containing the A3-C1-C2 domain).
  • B domain deletion refers to a factor VIII protein in which some or all removal of some or all of the amino acids between residues 711 and 1694 have been deleted, and which still preserves a biologically active FVIII molecule.
  • a range of B domain deletions can exist depending on which amino acid residues in the B domain is deleted and whereby the biological activity of the FVIII molecule is still preserved.
  • SQN Ser-Glu-Asn
  • Fractor VIII SQN deletion or "SQN deletion” as used herein refer to this deletion and to other deletions which preserve the single S-Q-N tripeptide sequence and which result in the deletion of the amino acids between the two B-domain SQN sequences (See PCT WO 91/09122 for a description of this amino acid sequence).
  • B-domain deleted form of factor VIII There are number of other B-domain deleted forms of factor VIII. cDNA's encoding all of these B-domain deleted factor VIII proteins can be inserted into lentiviral vector particles by using standard molecular biology techniques. For example cDNA molecules encoding the following B-domain factor VIII deletions can be constructed as described below:
  • a B domain deletion in which an IgG hinge region has been inserted can also be used.
  • a deletion of this type can be obtained from plasmid PSVF8- t ⁇ 2, which was designed to link the heavy and light chains with a short hinge region from immunoglobulin A.
  • the 5' untranslated leader and signal peptide are from the human Factor VII C cDNA, with the Kozak consensus sequence at the initiation codon as in pSVF8-302. A description of this vector is included in Chapman et al., U.S. Patent No. 5,595,886.
  • the 3' untranslated region is the same fused Factor VIII and tPA sequence as found in pSVF8-80K.
  • the construction may be completed in two steps: an oligomer with cohesive ends for EcoRI and Bell (117 bp) was cloned into a transfer vector, pF8GM7, the DNA sequence of the oligomer was checked by ml 3 subcloning and Sanger sequencing.
  • Plasmid pSVF8-500 encodes a factor VIII protein with amino acids 770 to 1656 of the full length Factor VIII deleted.
  • the threonine at position 1672 of the full-length factor VIII sequence was also deleted. The following is a description of the construction of the vector.
  • the pSVF8-500 plasmid is a derivative of pSVF8-302 in which the regions coding for the 92K and 80K domains are fused with a small connecting ⁇ - region of 21 amino acids, retaining the natural proteolytic processing sites.
  • This plasmid was constructed in the following manner:
  • a Sall-Kpnl fragment of 1984 bp containing the region coding for the 92K protein (except for the carboxyl terminal end) and BstXI-Sall fragment of 2186 bp containing the region coding for the carboxyl end of the 80K protein with 3' end untranslated region were isolated by gel electrophoresis after digestion of pSVF8- 302 with restriction enzymes.
  • a KpnI-EcoRI fragment containing the carboxyl end of the 92K protein and part of the ⁇ region (4 amino acids) was obtained by digestion of the Sail cassette from pSVF8-302 with Kpnl and EcoRI.
  • pSV500B ⁇ Thr was constructed from pSVF8-500. The threonine deletion at position 1672 was maintained. A synthetic linker was used to construct pSV500B ⁇ Thr. The linker extends from a unique Nrul site at Ser(765) to a unique
  • a third vector pSVF8-500B was constructed from pSV500B ⁇ Thr. This vector is identical to pSVF8-500B except that the codon for threonine 1672 was reinserted using standard mutagenesis methods. The relationship between, pSVF8-500B, pSVF8-500B, is further illustrated in the table below. Amino acid sequence numbers in the table were determined by reference to full-length factor VIII sequence.
  • the Bglll-Pfll 1.35 kb fragments of each modified cDNA listed above can be inserted into the lentiviral vector particles described herein using standard molecular biology procedures known to those of skill in the art and described herein.
  • the full-length factor VIII cDNA can also be inserted into the lentiviral vector particles of the invenfion (see, e.g., WO 96/21035).
  • a variety of Factor VIII deletions, mutations, and polypeptide analogs of Factor VIII can also be introduced into the lentiviral vector particles of the invention including lentiviral vector particles by modifications of the procedures described herein. These analogs include, for instance, those described in PCT Patent Publication Nos. WO 97/03193, WO 97/03194, WO 97/03195, and WO 97/03191, all of which are hereby incorporated by reference.
  • Hemophilia B can also be treated with systemically administered factor IX-expressing lentiviral vector particles including lentiviral vector particles.
  • Human factor IX deficiency (Christmas disease or Hemophilia B) affects primarily males because it is transmitted as sex-linked recessive trait. It affects about 2000 people in the US.
  • the human factor gene codes a 416 amino acids of mature protein.
  • the human factor IX cDNA can be obtained for instance by constructing plasmid pHflXl, as described by Kurachi and Davie, 1982, PNAS 79(21):6461-6464.
  • the cDNA sequence can be excised as a PstI fragment of about 1.5 kb, blunt ended using T4 DNA polymerase.
  • the factor cDNA fragment can be readily inserted, for example into a Srft site introduced into a lentiviral vector particle.
  • Lentiviral vector particles can be constructed using molecular biology techniques known to those of skill in the art. For instance, Factor V cDNA is obtained from pMT2-V (Jenny, 1987, Proc. Natl Acad. Sci. USA 54:4846; ATCC deposit
  • the 7 kb cDNA band is excised from agarose gels and cloned into lentiviral vector particles, using standard molecular biology techniques.
  • Either a full-length or a B-domain deletion or substitution of the factor V cDNA can be expressed by the gene therapy vectors of the invention.
  • Factor V B- domain deletions such as those reported by Marquette, 1995, Blood 86:3026, and Kane, 1990, Biochemistry 29:6762, can be made as described by these authors.
  • Lentiviral vector particles capable of expressing ATIII cDNA can be readily constructed using standard molecular biology techniques known to those of skill in the art.
  • a lentiviral vector particle expressing AT III can be constructed from the vector pKT218 (Prochownik, 1983, J. Biol Chem. 255:8389; ATCC number 57224/57225) by excision with PstI.
  • the 1.6 kb cDNA insert can be recovered from agarose gels and cloned into the PstI site of vector SK-.
  • the insert can be recovered by restriction enzyme digestion and cloned into lentiviral vector particles described herein by the restriction enzymes.
  • the lentiviral vector particles of the invention capable of expressing Protein C can be made using a wide variety of techniques given the present disclosure.
  • protein C cDNA will be obtained by restriction enzyme digestion of published vector (Foster, 1984, Proc. Natl Acad. Sci. USA 57:4766; Beckmann, 1985, Nucleic Acids Res 13:5233).
  • the 1.6 kb cDNA insert can be recovered from agarose gels and cloned into the multiple cloning site of vector SK- under standard conditions.
  • the insert can be recovered by restriction enzyme digestion and cloned into a lentiviral vector particle; for example, excision by XhoI/NotI digestion followed by cloning into XhoI/NotI digested lentiviral vector particle.
  • Prothrombin Lentiviral vector particles expressing prothrombin and its variants can be constructed by methods known to those of skill in the art, by using variations on the methods described herein.
  • prothrombin cDNA can be obtained by restriction enzyme digestion of a published vector (Degen (1983) Biochemistry 22:2087).
  • the 1.9 kb cDNA insert can be recovered from agarose gels and cloned into the multiple cloning site of vector SK-.
  • the insert can be recovered by restriction enzyme digestion and cloned into a lentiviral vector particle using restriction enzyme digestion
  • thrombomodulin cDNA can be obtained from the vector puc! 9TM15 (Jackman, 1987, Proc. Natl. Acad. Sci. USA 54:6425; Shirai, 1988, J. Biochem. 705:281 ; Wen , 1987, Biochemistry 26:4350; Suzuki, 1987, EMBO J 6:1891 ; ATCC number 61348,61349) by excision with Sail.
  • the 3.7 kb cDNA insert can be recovered from agarose gels and cloned into the Sail site of lentiviral vector particle.
  • proteins useful for treatment of hereditary disorders that can be expressed in vivo by the methods of invention.
  • Many genetic diseases caused by inheritance of defective genes result in the failure to produce normal gene products, for example, thalassemia, phenylketonuria, Lesch-Nyhan syndrome, severe combined immunodeficiency (SCID), hemophilia, A and B, cystic fibrosis, Duchenne's Muscular Dystrophy, inherited emphysema and familial hypercholesterolemia (Mulligan et al, 1993, Science 260:926; Anderson et al, 1992, Science 256:808; Friedman et al, 1989, Science 244: 1275).
  • genetic diseases may result in the absence of a gene product
  • endocrine disorders such as diabetes and hypopituitarism
  • Gene therapy by the methods of the invention is a powerful approach for treating these types of disorders. This therapy involves the introduction of normal recombinant genes into somatic cells so that new or missing proteins are produced inside the cells of a patient.
  • a number of genetic diseases can be treated by gene therapy, including adenine deaminase deficiency, cystic fibrosis, ⁇ .-antitrypsin deficiency, Gaucher's syndrome, as well as non-genetic diseases.
  • lactase for treatment of hereditary lactose intolerance
  • AD for treatment of ADA deficiency
  • alpha-1 antitypsin for treatment of alpha- 1 antitrypsin deficiency.
  • familial hypercholesterolemia is a disease characterized clinically by a lifelong elevation of low density lipoprotein (LDL), the major cholesterol-transport lipoprotein in human plasma; Pathologically by the deposition of LDL-derived cholesterol in tendons, skin and arteries leading to premature coronary heart disease; and genetically by autosomal dominant inherited trait.
  • LDL low density lipoprotein
  • Hetrozygotes number about 1 in 500 persons worldwide. Their cells are able to bind cholesterol at about half the rate of normal cells. Their plasma cholesterol levels show two fold elevation starting at birth. Homozygotes number 1 in 1 million persons. They have severe cholesterolemia with death occurring usually before age 20.
  • the disease (Arteriosclerosis) depends on geography. It affects 15.5 per 100,000 individuals in the U.S.
  • Lentiviral vector particles expressing the LDL receptor for treatment of disorders manifesting with elevated serum LDL can be constructed by techniques known to those of skill in the art.
  • An example of a lentiviral vector particle expressing LDS receptor is shown in example 32 herein.
  • tissue factor inhibitory protein TFPI
  • sustained in vivo expression of tissue factor inhibitory protein is useful for treatment of conditions including sepsis and DIC and in preventing reperfusion injury.
  • TFPI tissue factor inhibitory protein
  • Nucleic acid sequences encoding various forms of TFPI can be obtained, for example, as described in US Patent Nos. 4,966,852; 5, 106,833; and 5,466,783, and can be incorporated in lentiviral vector particles as is described herein.
  • EPO erythropoietin
  • leptin can also be expressed in vivo by lentiviral vector particles according to the methods of the invention.
  • EPO is useful in gene therapy treatment of a variety of disorders including anemia (see PCT publication number WO 95/13376 entitled “Gene Therapy for Treatment of Anemia”.)
  • Sustained gene therapy delivery of leptin by the methods of the invention is useful in treatment of obesity.
  • Lentiviral vector particle expressing EPO or leptin can readily be produced using the methods described herein and the constructs described in these two patent publications.
  • sustained in vivo systemic production of apolipoprotein E or apolipoprotein A by the lentiviral vector particles of the invention can be used for treatment of hyperlipidemia.
  • sustained production of angiotensin receptor inhibitor T.L. Goodfriend, et al, 1996, N. Engl. J. Med. 554:1469
  • angiotensin receptor inhibitor T.L. Goodfriend, et al, 1996, N. Engl. J. Med. 554:1469
  • the long term in vivo systemic production of angiostatin by the lentiviral vector particles of the invention is useful in the treatment of a variety of tumors. (See O'Reilly et al, 1996, Nature Med. 2:689.
  • the present invention also provides lentiviral vector particles which can, among other functions, direct the expression of one or more cytokines or cytokine receptors.
  • cytokines can have negative effects resulting in certain pathological conditions.
  • most resting T-cells, B cells, large granular lymphocytes and monocytes do not express IL-2R (receptor).
  • IL-2R receptor
  • IL-2R is expressed by abnormal cells in patients with certain leukemias (ATL, Hairy-cell, Hodgkins, acute and chronic granulocytic), autoimmune diseases, and is associated with allograft rejection.
  • therapy may be effected by increasing the serum concentration of the soluble form of the cytokine receptor.
  • a lentiviral vector can be engineered to produce both soluble IL-2R and IL-2R, creating a high affinity soluble receptor. In this configuration, serum IL-2 levels would decrease, inhibiting the paracrine loop. This same strategy also may be effective against autoimmune diseases.
  • autoimmune diseases e.g., Rheumatoid arthritis, SLE
  • blocking the action of IL-2 by increasing the serum level of receptor may also be utilized in order to treat such autoimmune diseases.
  • IL-1 consists of two polypeptides, IL-1 and IL-1, each of which has plieotropic effects.
  • IL-1 is primarily synthesized by mononuclear phagocytes, in response to stimulation by microbial products or inflammation.
  • IL-1 Receptor antagonist IL-1 Receptor antagonist
  • This IL-1R antagonist has the same molecular size as mature IL-1 and is structurally related to it. However, binding of IL-lRa to the IL-1R does not initiate any receptor signaling.
  • IL-1 does not seem to play an important role in normal homeostasis.
  • antibodies to IL-1 receptors reduce inflammation and anorexia due to endotoxins and other inflammation inducing agents.
  • IL-1 induces secondary compounds which are potent vasodilators.
  • exogenously supplied IL-1 decreases mean arterial pressure and induces leukopenia.
  • Neutralizing antibody to IL-1 reduced endotoxin- induced fever in animals.
  • lentiviral vector particles may be engineered to produce a soluble receptor or more specifically the IL-lRa molecule.
  • a single injection of IL- lRa producing vector particles could replace the current approach requiring a constant infusion of recombinant IL-1R.
  • Cytokine responses may also be involved in the failure to control or resolve infectious diseases. Perhaps the best studied example is non-healing forms of leishmaniasis in mice and humans which have strong, but counterproductive T H 2-dominated responses. Similarly, lepromotomatous leprosy is associated with a dominant, but inappropriate T H 2 response. In these conditions, lentiviral vector particles may be useful for increasing circulating levels of IFN gamma, as opposed to the site-directed approach proposed for solid tumor therapy. IFN gamma is produced by T H -1 T-cells, and functions as a negative regulator of T H -2 subtype proliferation. IFN gamma also antagonizes many of the IL-4 mediated effects on B-cells, including isotype switching to IgE.
  • IL-4 acts on differentiating T-cells to stimulate T H -2 development, while inhibiting T H -1 responses.
  • lentivirus-based gene therapy may also be accomplished in conjunction with traditional allergy therapeutics.
  • One possibility is to deliver lentiviral vector particles which produces IL4R with small amounts of the offending allergen (i.e., traditional allergy shots). Soluble IL-4R would prevent the activity of IL-4, and thus prevent the induction of a strong T H -2 response.
  • the lentiviral vector particles including lentiviral vector particles and the methods of administration described are useful for treatment of viral hepatitis, including hepatitis B and hepatitis C.
  • the lentiviral vector particles of the invention can be used to express interferon-alpha for treatment of viral hepatitis.
  • lentiviral vector particles injected intravenously preferentially transduce liver cells.
  • the methods of intravenous delivery described herein for lentiviral vector particles can be used for treatment of liver diseases such as hepatitis and in particular viral hepatitis, in which therapeutic proteins expressed by the lentiviral vector particles such as lentiviral vector particles can be delivered preferentially to the liver.
  • Alpha-interferon is a secreted protein induced in B lymphocytes, macrophages and null lymphocytes by foreign cells, virus- infected cells, tumor cells, bacterial cells and products and viral envelopes.
  • the mechanism of antiviral action of interferon is by inducing the synthesis of effector proteins: two of the most important are 2', 5'-oligo-adenylate synthetase (OAS) and dsRNA-dependent protein kinase (RDPK).
  • OFAS 5'-oligo-adenylate synthetase
  • RDPK dsRNA-dependent protein kinase
  • OAS synthesizes adenylate oligomers that activate RNAaseL, which degrades viral single stranded RNA.
  • RDPK phosphorylates initiation factor eIF-2a which results in the inhibition of viral protein translation.
  • alpha interferon has immunomodulatory effects that are important against viral infections. These immunomodulatory effects are: enhancement of the expression of both Class I and class II major histocompatibility complex (MHC) molecules, modulation of the expression of the interleukin-2 receptor, TNF- ⁇ receptor, transferrin receptor, enhancement of spontaneous natural killer (NK) cell cytotoxicity and modulation of antibody production by B cells.
  • MHC major histocompatibility complex
  • Localized expression of interferon alpha in the liver from a lentiviral vector particle such as a lentiviral vector particle can be an effective treatment for hepatitis. While not wishing to bound by theory, delivery of alpha interferon at the site of infection by the gene therapy vectors of the invention, including lentiviral vector particles, results in high local concentration of the cytokine thereby focusing the antiviral and immunological effects to the adjacent infected hepatocytes.
  • a further advantage of this treatment is that the current systemic mode of systemic alpha interferon therapy may either be unnecessary or be reduced in dose and frequency of treatment. This reduction can reduce the adverse side effects associated with the systemic delivery of alpha interferon.
  • the gene therapy approaches described herein may be used in combination with administration of alpha-interferon protein formulations.
  • interferon-alpha There are at least 24 different human alpha interferon genes or pseudogenes. There are two distinct families (I and II); mature human alpha interferon (I) are 166 amino acids long (one is 165 amino acids) whereas alpha interferon (II) have 172 amino acids. Eighteen genes are in the alpha interferon I family, including at least four pseudogenes. Six genes are in the alpha interferon II family, including five pseudogenes (Callard, R., and Gearing, A., Cytokine Facts Book, Academic Press, 1994 pp. 148-154).
  • Example 33 herein we use alpha interferon 2a, 2b, 2c, 54 and 76, all members of the alpha interferon (I) family. Similar techniques can be used for inserting other members of the alpha interferon I family (such as alpha interferon F and N) into lentiviral vector particles. Thus other biologically active forms of alpha-interferon in addition to 2a, 2b, 2c, 54 and 76 as described herein can also be expressed by the lentiviral vector particles of the invenfion and used for treatment of viral hepatitis.
  • Patients with viral hepatitis can be treated a combination gene therapy approach.
  • a lentiviral vector particle expressing a protein drug such as alpha-interferon can be administered intravenously or directly to the liver by methods described herein.
  • This therapeutic approach can be combined with intramuscular delivery of a lentiviral vector particle expressing a hepatitis B or hepatitis C antigen for inducing a immune response against the hepatitis virus.
  • Specific hepatitis B and C antigens useful in this type of therapy and the construction of lentiviral vector particles expressing such antigens are described herein and in PCT Patent Publication No. WO 93/15207.
  • molecularly cloned genomes which encode the hepatitis B virus may be obtained from a variety of sources including, for example, the American Type Culture Collection (ATCC, Rockville, Maryland).
  • ATCC No. 45020 contains the total genomic DNA of hepatitis B (extracted from purified Dane particles) (see Figure 3 of Blum et al, 1989, TIG 5(5):154-158) in the Bam HI site of pBR322 (Moriarty et al, 1981, Proc. Natl Acad. Sci. USA 75:2606-2610). (Note that correctable enors occur in the sequence of ATCC No. 45020.)
  • lentiviral vector suicide vectors to limit the spread of wild-type lentivirus in the packaging/producer cell lines.
  • the lentiviral vector particles contains a prodrug activating enzyme as discussed above which, upon administration of the prodrug (e.g., gancyclovir) results in the death of cells containing the vector particles.
  • Lentiviral vectors to Prevent the Spread of Metastatic Tumors One further aspect of the present invention relates to the use of lentiviral vector particles for inhibiting or reducing the invasiveness of malignant neoplasms. Briefly, the extent of malignancy typically relates to vascularization of the tumor. One cause for tumor vascularization is the production of soluble tumor angiogenesis factors (TAP) (Paweletz et al., Crit. Rev. Oncol. Hematol. 9:197, 1989) expressed by some tumors. Within one aspect of the present invention, tumor vascularization may be slowed utilizing lentiviral vectors to express antisense or ribozyme RNA molecules specific for TAP.
  • TAP tumor angiogenesis factors
  • anti-angiogenesis factors may be expressed either alone or in combination with the above-described ribozymes or antisense sequences in order to slow or inhibit tumor vascularization.
  • lentiviral vector particles can also be used to express an antibody specific for the TAF receptors on sunounding tissues. 10. Modulation of Transcription Factor Activity
  • lentiviral vector particles may be utilized in order to regulate the growth control activity of transcription factors in the infected cell.
  • transcription factors directly influence the pattern of gene expression through sequence-specific tra «s-activation or repression (Karin, New Biologist 27:126-131, 1990).
  • mutated transcription factors represent a family of oncogenes.
  • Lentiviral vector particles can be used, for example, to return control to tumor cells whose unregulated growth is activated by oncogenic transcription factors, and proteins which promote or inhibit the binding cooperatively in the formation of homo- and heterodimer /raws-activating or repressing transcription factor complexes.
  • the nuclear oncogene c-myc is expressed by proliferating cells and can be activated by several distinct mechanisms, including retroviral insertion, amplification, and chromosomal translocation.
  • the Max protein is expressed in quiescent cells and, independently of c-myc, either alone or in conjunction with an unidentified factor, functions to repress expression of the same genes activated by the myc/Max heterodimer (Cole, Cell 65:715-716, 1991).
  • Inhibition of c-myc or c- ⁇ ?2yc/Max proliferation of tumor cells may be accomplished by the overexpression of Max in target cells controlled by lentiviral vectors.
  • the Max protein is only 160 amino acids (conesponding to 480 nucleotide RNA length) and is easily incorporated into a lentiviral vector either independently, or in combination with other genes and/or antisense/ribozyme moieties targeted to factors which release growth control of the cell.
  • Modulation of homo/hetero-complex association is another approach to control transcription factor activated gene expression. For example, transport from the cytoplasm to the nucleus of the trans-activating transcription factor NF-B is prevented while in a heterodimer complex with the inhibitor protein IB.
  • IB Upon induction by a variety of agents, including certain cytokines, IB becomes phosphorylated and NF-B is released and transported to the nucleus, where it can exert its sequence-specific trans-activating function (Baeuerle and Baltimore, Science 242:540-546, 1988).
  • the dissociation of the NF-B/IB complex can be prevented by masking with an antibody the phosphorylation site of IB. This approach would effectively inhibit the trans-activation activity of the NF-IB transcription factor by preventing its transport to the nucleus.
  • Expression of the IB phosphorylation site specific antibody or protein in target cells may be accomplished with an lentivirus gene transfer vector.
  • An approach similar to the one described here could be used to prevent the formation of the trans-activating transcription heterodimer factor AP-1 (Turner and Tijan, Science 245:1689-1694, 1989), by inhibiting the association between the jun and fos proteins.
  • lentiviral vector particle which has been purified or concentrated may be preserved or formulated into a pharmaceutical compound or medicament by first adding a sufficient amount of a formulation buffer to the media containing the lentiviral vector particle, in order to form an aqueous suspension.
  • the formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering component in water.
  • a “buffering compound” or “buffering component” should be understood to refer to a substance that functions to maintain the aqueous suspension at a desired pH.
  • the aqueous solution may also contain one or more amino acids.
  • the lentiviral vector particle can also be preserved in a purified form. More specifically, prior to the addition of the formulation buffer, the crude lentiviral vector particle described above may be clarified by passing it through a filter, and then concentrated, such as by a cross flow concentrating system (Filtron Technology Corp., Nortborough, MA). Within one embodiment, DNase is added to the concentrate to digest exogenous DNA. The digest is then diafiltrated to remove excess media components and establish the lentiviral vector particle in a more desirable buffered solution. The diafiltrate is then passed over a Sephadex S-500 gel column and a purified lentiviral vector particle is eluted.
  • a cross flow concentrating system Frtron Technology Corp., Nortborough, MA
  • the formulation buffer is an aqueous solution that contains a saccharide, a high molecular weight structural additive, and a buffering component in water.
  • the aqueous solution may also contain one or more amino acids.
  • the crude lentiviral vector particle can also be purified by ion exchange column chromatography (see U.S. Patent Application Serial No. 08/093,436).
  • the crude lentiviral vector particle is clarified by passing it through a filter, and the filtrate loaded onto a column containing a highly sulfonated cellulose matrix.
  • the lentiviral vector particle is eluted from the column in purified form by using a high salt buffer.
  • the high salt buffer is then exchanged for a more desirable buffer by passing the eluate over a molecular exclusion column.
  • a sufficient amount of formulation buffer is then added, as discussed above, to the purified lentiviral vector particle and the aqueous suspension is either dried immediately or stored, preferably at -70°C.
  • the aqueous suspension in crude or purified form can be dried by lyophilization or evaporation at ambient temperature.
  • lyophilization involves the steps of cooling the aqueous suspension below the glass transition temperature or below the eutectic point temperature of the aqueous suspension, and removing water from the cooled suspension by sublimation to form a lyophilized lentivirus.
  • aliquots of the formulated lentiviral vector particle are placed into an Edwards Refrigerated Chamber (3 shelf RC3S unit) attached to a freeze dryer (Supermodulyo 12K).
  • a multistep freeze drying procedure as described by Phillips et al.
  • the lentiviral vector particle is stable and may be stored at -20°C to 25°C.
  • water is removed from the aqueous suspension at ambient temperature by evaporation.
  • water is removed through spray drying (EP 520,748).
  • spray drying Within the spray drying process, the aqueous suspension is delivered into a flow of preheated gas, usually air, whereupon water rapidly evaporates from droplets of the suspension.
  • Spray drying apparatus are available from a number of manufacturers (e.g., Drytec, Ltd., Tonbridge, England; Lab- Plant, Ltd., Huddersfield, England). Once dehydrated, the lentiviral vector particle is stable and may be stored at -20°C to 25°C.
  • the resulting moisture content of the dried or lyophilized lentivirus may be determined through use of a Karl-Fischer apparatus (EM Science AquastarTM V1B volumetric titrator, Cherry Hill, NJ), or through a gravimetric method.
  • the aqueous solutions used for formulation, as previously described, are composed of a saccharide, high molecular weight structural additive, a buffering component, and water.
  • the solution may also include one or more amino acids. The combination of these components act to preserve the activity of the lentiviral vector particle upon freezing and lyophilization, or drying through evaporation.
  • saccharide is lactose
  • other saccharides may be used, such as sucrose, mannitol, glucose, trehalose, inositol, fructose, maltose or galactose.
  • combinations of saccharides can be used, for example, lactose and mannitol, or sucrose and mannitol (e.g., a concentration of lactose is 3%-4% by weight.
  • the concentration of the saccharide ranges from 1% to 12% by weight.
  • the high molecular weight structural additive aids in preventing viral aggregation during freezing and provides structural support in the lyophilized or dried state.
  • structural additives are considered to be of "high molecular weight" if they are greater than 5000 m.w.
  • a preferred high molecular weight structural additive is human serum albumin.
  • other substances may also be used, such as hydroxyethyl-cellulose, hydroxymethyl-cellulose, dextran, cellulose, gelatin, or povidone.
  • a particularly prefened concentration of human serum albumin is 0.1% by weight.
  • the concentration of the high molecular weight structural additive ranges from 0.1% to 10% by weight.
  • amino acids function to further preserve viral infectivity upon cooling and thawing of the aqueous suspension.
  • amino acids function to further preserve viral infectivity during sublimation of the cooled aqueous suspension and while in the lyophilized state.
  • a prefened amino acid is arginine, but other amino acids such as lysine, ornithine, serine, glycine, glutamine, asparagine, glutamic acid or aspartic acid can also be used.
  • a particularly prefened arginine concentration is 0.1% by weight.
  • the amino acid concentration ranges from 0.1% to 10% by weight.
  • the buffering component acts to buffer the solution by maintaining a relatively constant pH.
  • buffers may be used, depending on the pH range desired, preferably between 7.0 and 7.8. Suitable buffers include phosphate buffer and citrate buffer.
  • a particularly prefened pH of the lentiviral vector particle formulation is 7.4, and a prefened buffer is tromethamine.
  • the aqueous solution contain a neutral salt which is used to adjust the final formulated lentiviral vector particle to an appropriate iso-osmotic salt concentration.
  • Suitable neutral salts include sodium chloride, potassium chloride or magnesium chloride.
  • a prefened salt is sodium chloride.
  • Aqueous solutions containing the desired concentration of the components described above may be prepared as concentrated stock solutions.
  • One method of preserving lentiviral vector particles in a lyophilized state for subsequent reconstitution comprises the steps of (a) combining an infectious lentiviral vector particle with an aqueous solution to form an aqueous suspension, the aqueous suspension including 4%> by weight of lactose, 0.1% by weight of human serum albumin, 0.03% or less by weight of NaCl, 0.1% by weight of arginine, and an amount of tromethamine buffer effective to provide a pH of the aqueous suspension of approximately 7.4, thereby stabilizing the infectious lentiviral vector particle; (b) cooling the suspension to a temperature of from -40°C to -45°C to form a frozen suspension; and (c) removing water from the frozen suspension by sublimation to form a lyophilized composition having less than 2% water by weight of the lyophilized composition, the composition being capable of infecting mammalian cells upon reconstitution.
  • the lentiviral vector particle be replication defective and suitable for administration into humans upon reconstitution. It will be evident to those skilled in the art given the disclosure provided herein that it may be preferable to utilize certain saccharides within the aqueous solution when the lyophilized lentivirus is intended for storage at room temperature. More specifically, it is preferable to utilize disaccharides, such as lactose or trehalose, particularly for storage at room temperature.
  • the lyophilized or dehydrated Lentiviruses of the subject invention may be reconstituted using a variety of substances, but are preferably reconstituted using water. In certain instances, dilute salt solutions which bring the final formulation to isotonicity may also be used.
  • aqueous solutions containing components known to enhance the activity of the reconstituted lentivirus include cytokines, such as IL-2, polycations, such as protamine sulfate, or other components which enhance the transduction efficiency of the reconstituted lentivirus.
  • cytokines such as IL-2
  • polycations such as protamine sulfate
  • Lyophilized or dehydrated lentiviral vector particle may be reconstituted with any convenient volume of water or the reconstituting agents noted above that allow substantial, and preferably total solubilization of the lyophilized or dehydrated sample.
  • recombinant lentiviral particles of the present invention may be administered to a wide variety of locations including, for example, into sites such as the cerebral spinal fluid, bone manow, joints, arterial endothelial cells, rectum, buccal/sublingual, vagina, the lymph system, to an organ selected from the group consisting of lung, liver, spleen, skin, blood and brain, or to a site selected from the group consisting of tumors and interstitial spaces.
  • the lentiviral vector particle may be administered intrarticularly, intraocularly, intranasally, sublinually, orally, topically, intravesically, intrathecally, topically, intravenously, intraperitoneally, intracranially, intramuscularly, or subcutaneously.
  • Other representative routes of administration include gastroscopy, ECRP and colonoscopy, which do not require full operating procedures and hospitalization, but may require the presence of medical personnel.
  • compositions of the present invention include the following:
  • Oral administration is easy and convenient, economical (no sterility required), safe (over dosage can be treated in most cases), and permits controlled release of the active ingredient of the composition (the lentiviral vector particle).
  • the lentiviral vector particle will be subject to "first pass effect" by hepatic metabolism and gastric acid and enzymatic degradation.
  • efficient plasma levels may not be reached, a patient's cooperation is required, and food can affect absorption.
  • Prefened embodiments of the present invention include the oral administration of lentiviral vector particles that express genes encoding erythropoietin, insulin, GM-CSF cytokines, various polypeptides or peptide hormones, their agonists or antagonists, where these hormones can be derived from tissues such as the pituitary, hypothalamus, kidney, endothelial cells, liver, pancreas, bone, hemopoetic manow, and adrenal.
  • Such polypeptides can be used for induction of growth, regression of tissue, suppression of immune responses, apoptosis, gene expression, blocking receptor-ligand interaction, immune responses and can be treatment for certain anemias, diabetes, infections, high blood pressure, abnormal blood chemistry or chemistries (e.g., elevated blood cholesterol, deficiency of blood clotting factors, elevated LDL with lowered HDL), levels of Alzheimer associated amaloid protein, bone erosion/calcium deposition, and controlling levels of various metabolites such as steroid hormones, purines, and pyrimidines.
  • the lentiviral vector particles are first lyophilized, then filled into capsules and administered.
  • Buccal/sublingual administration is a convenient method of administration that provides rapid onset of action of the active component(s) of the composition, and avoids first pass metabolism. Thus, there is no gastric acid or enzymatic degradation, and the absorption of lentiviral vector particles is feasible. There is high bioavailability, and virtually immediate cessation of treatment is possible. Conversely, such administration is limited to relatively low dosages (typically about 10- 15 mg), and there can be no simultaneous eating, drinking or swallowing.
  • Prefened embodiments of the present invention include the buccal/sublingual administration of lentiviral vector particles that contain genes encoding self and/or foreign MHC, or immune modulators, for the treatment of oral cancer; the treatment of Sjogren's syndrome via the buccal/sublingual administration of such lentiviral vector particles that contain IgA or IgE antisense genes; and, the treatment of gingivitis and periodontitis via the buccal/sublingual administration of IgG or cytokine antisense genes.
  • Rectal administration provides a negligible first pass metabolism effect (there is a good blood/lymph vessel supply, and absorbed materials drain directly into the inferior vena cava), and the method is suitable of children, patients with emesis, and the unconscious.
  • the method avoids gastric acid and enzymatic degradation, and the ionization of a composition will not change because the rectal fluid has no buffer capacity (pH 6.8; charged compositions absorb best).
  • lipidophilic and water soluble compounds are prefened for absorption by the rectal mucosa, and absorption enhancers (e.g., salts, EDTA, NSAID) may be necessary.
  • absorption enhancers e.g., salts, EDTA, NSAID
  • Prefened embodiments of the present invention include the rectal administration of lentiviral vector particles that contain genes encoding colon cancer antigens, self and/or foreign MHC, or immune modulators.
  • Nasal administration avoids first pass metabolism, and gastric acid and enzymatic degradation, and is convenient.
  • nasal administration is useful for lentiviral vector particle administration wherein the lentiviral vector particle is capable of expressing a polypeptide with properties as described herein. Conversely, such administration can cause local irritation, and absorption can be dependent upon the state of the nasal mucosa.
  • Pulmonary administration also avoids first pass metabolism, and gastric acid and enzymatic degradation, and is convenient. Further, pulmonary administration permits localized actions that minimize systemic side effects and the dosage required for effectiveness, and there can be rapid onset of action and self-medication. Conversely, at times only a small portion of the administered composition reaches the brochioli/alveoli, there can be local irritation, and overdosing is possible. Further, patient cooperation and understanding is prefened, and the propellant for dosing may have toxic effects.
  • Prefened embodiments of the present invention include the pulmonary administration of lentiviral vector particles that express genes encoding IgA or IgE for the treatment of conditions such as asthma, hay fever, allergic alveolitis or fibrosing alveolitis, the CFTR gene for the treatment of cystic fibrosis, and protease and collagenous inhibitors such as ⁇ - 1 -antitrypsin for the treatment of emphysema.
  • lentiviral vector particles that express genes encoding IgA or IgE for the treatment of conditions such as asthma, hay fever, allergic alveolitis or fibrosing alveolitis, the CFTR gene for the treatment of cystic fibrosis, and protease and collagenous inhibitors such as ⁇ - 1 -antitrypsin for the treatment of emphysema.
  • CFTR gene for the treatment of cystic fibrosis
  • protease and collagenous inhibitors such as ⁇ - 1 -antitryps
  • Ophthalmic administration provides local action, and permit prolonged action where the administration is via inserts. Further, avoids first pass metabolism, and gastric acid and enzymatic degradation, and permits self-administration via the use of eye-drops or contact lens-like inserts. Conversely, the administration is not always efficient, because the administration induces tearing.
  • Prefened embodiments of the present invention include the ophthalmic administration of lentiviral vector particles that express genes encoding IgA or IgE for the treatment of hay fever conjunctivitis or vernal and atomic conjunctivitis; and ophthalmic administration of lentiviral vector particles that contain genes encoding melanoma specific antigens (such as high molecular weight-melanoma associated antigen), self and/or foreign MHC, or immune modulators.
  • melanoma specific antigens such as high molecular weight-melanoma associated antigen
  • Transdermal administration permits rapid cessation of treatment and prolonged action leading to good compliance. Further, local treatment is possible, and avoids first pass metabolism, and gastric acid and enzymatic degradation. Conversely, such administration may cause local initation, is particularly susceptible to tolerance development, and is typically not prefened for highly potent compositions.
  • Prefened embodiments of the present invention include the transdermal administration of lentiviral vector particles that express genes encoding IgA or IgE for the treatment of conditions such as atopic dermatitis and other skin allergies; and transdermal administration of lentiviral vector particles encoding genes encoding melanoma specific antigens (such as high molecular weight-melanoma associated antigen), self and/or foreign MHC, or immune modulators.
  • Vaginal administration provides local treatment and one prefened route for hormonal administration. Further, such administration avoids first pass metabolism, and gastric acid and enzymatic degradation, and is prefened for administration of compositions wherein the lentiviral vector particles express peptides.
  • Prefened embodiments of the present invention include the vaginal administration of lentiviral vector particles that express genes encoding self and/or foreign MHC, or immune modulators.
  • Other prefened embodiments include the vaginal administration of genes encoding the components of sperm such as histone, flagellin, etc., to promote the production of sperm-specific antibodies and thereby prevent pregnancy.
  • lentiviral vector particles vectors encoding immunoglobulin antisense genes, which genes interfere with the production of sperm-specific antibodies.
  • Intravesical administration permits local treatment for urogenital problems, avoiding systemic side effects and avoiding first pass metabolism, and gastric acid and enzymatic degradation. Conversely, the method requires urethral catheterization and requires a highly skilled staff.
  • Preferred embodiments of the present invention include intravesical administration of lentiviral vector particle encoding antitumor genes such as a prodrug activation gene such thymidine kinase or various immunomodulatory molecules such as cytokines.
  • Endoscopic retrograde cystopancreatography (goes through the mouth; does not require piercing of the skin) takes advantage of extended gastroscopy, and permits selective access to the biliary tract and the pancreatic duct. Conversely, the method requires a highly skilled staff, and is unpleasant for the patient.
  • routes of administration described herein may be accomplished simply by direct administration using a needle, catheter or related device.
  • one or more dosages may be administered directly in the indicated manner at dosages greater than or equal to 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 or l0 ⁇ cfu.
  • Lentiviral vector particle may be delivered to the target from outside of the body (as an outpatient procedure) or as a surgical procedure, where the vector is administered as part of a procedure with other purposes, or as a procedure designed expressly to administer the vector.
  • Other routes and methods for administration include the non-traumatic routes disclosed within PCT/US95/16967, as well as administration via multiple sites as disclosed within PCT/US95/16471.
  • Plasmid pSK- ⁇ H3 is first constructed by digestion, filling and blunt end ligation of the unique Hin ⁇ lll site of pBluescript SK(-) (Stratagene, La Jolla, CA).
  • HIV-1 LTR from the molecular clone pNL4-3 (Adachi et al., J.
  • Virol. 1986, 59, 284/ NIH AIDS Research and Reference reagent program catalog #114 is amplified by Polymerase Chain Reaction (PCR) using oligomers LTRB5 : 5' TAG
  • TAG GAT CCT TTC GCT TTC AAG TCC C 3' (Sequence ID No. ), which both display a BamHl restriction site at their 5' end.
  • the amplified fragment of 681 bp in length is cloned into the unique BamHl site of pSK- ⁇ H3.
  • the resulting plasmid is named pHIV-LTR.
  • the 1181 bp Htndlll to Hin ⁇ l fragment of pNL4-3, comprising the 3' end of the 5' LTR and the 5' part of the gag gene is cloned into the unique Hin ⁇ lll site of pbluescript SK(-) to create pHIV-H3F5'.
  • the 916 bp Hin ⁇ lll to Sphl fragment from pHIV-H3F5' is ligated with the 3482 bp Hin ⁇ lll to EcoRI fragment from pHIV-LTR, using a Sphl- ⁇ coRI adaptor to give pHIV-LTR5'.
  • the initiation codon region is modified from GAG ATG GGT to
  • GAG AAC CGG T (Sequence ID No. ) by site directed mutagenesis (Muta-gene kit, Biorad, Hercules, CA) using the mutated oligonucleotide 5' GGA GGC TAG AAG
  • the 719 bp Xho I to Hzndlll fragment from pNL4-3 is ligated with the 3067 bp Xba I to Hin ⁇ lll fragment from pHIV-LTR- ⁇ RI/Xho using a Xba l-Xho I adaptor to give pLTR-HIV3'.
  • vHIV-I To create the HIV- 1 -based vector backbone, named vHIV-I, the 1510 bp Not I to Xho I fragment from pHIV-LTR5' is inserted into the Not I and Xho I sites of pHIV-LTR3' (see Figure 1).
  • nuclear transport elements can be added to vHIV.
  • the HIV-1 Rev-responsive element (RRE) is amplified by PCR from pNL4-3 using the oligomers RREl : 5' GCA AGC TTC TGC AGA GCA GTG GGA
  • the RRE fragment is extracted from pRRE using the enzymes Eco RI and Cla I and inserted into the Eco RI and Cla I sites of vHIV to give vHIVR.
  • HBV Hepatitis B Virus
  • PRE posttranscriptional regulatory element
  • MPMV Mason-Pfizer monkey Virus
  • CTE constitutive transport element
  • the beta-galactosidase gene is put under the control of two different tissue-specific promoters. More specifically, in order to induce liver tissue specific expression of the transgene, the 88 bp Hinc II to Rsa I fragment from the construct p ⁇ CCAT7, (Yee, Science, 1989, 246, 658), which contains the Hepatitis B Virus (HBV) liver specific enhancer, is cloned upstream the Herpes simplex virus (HSV) thymidine kinase (TK) gene promoter to drive the expression of the beta-galactosidase gene in place of the CMV promoter.
  • HBV Herpes simplex virus
  • TK thymidine kinase
  • the CD2 gene enhancer (Lake et al, EMBO J. 9:3129, 1990) is cloned upstream the HSV TK gene promoter to induce lymphocyte-specific expression.
  • two types of dicistronic constructs are designed.
  • the 2.1 kb Bam HI to Hin ⁇ III fragment encoding the firefly luciferase gene sequence (luc) and the Neomycin phosphotransferase gene sequence (neo) distant of 78 nucleotides from pLL78NL is inserted in the Sal I to Sal I backbone of VHRC-beta-gal to create vHRCL78N.
  • the 78 nucleotide linker between the two genes allows reinitiation of translation of the second open reading frame before the large ribosome subunit detaches from the mRNA.
  • PO-IRES poliovirus internal ribosome entry site
  • the packaging cassette pCMV-HIV-1 To construct the packaging cassette pCMV-HIV-1, the 0.7-kilobase pair (kb) BamHI-SphI fragment with a 19-base pair (bp) deletion in the putative packaging signal of pCMVDPlDenvpA ( Parolin et al., J. Virol 65:3888-3895, 1994) was fused with the 8-kb Sphl-Hindlll (from position 1447 to 9606) fragment of pNL4-3 (containing a full-length infectious HIV-1 genome, Adachi et al., J. Virol.
  • pCMV-HIV-1 was digested with Ndel (at position 5123 in pNL4-3) and repaired with the Klenow fragment to create a 2-bp insertion in the coding region of the vif gene.
  • Vpu initiation codon of Vpu was mutated by site directed mutagenesis (Mutagene kit, Biorad, Hercules, CA) using the oligonucleotide 5 GCTACTATTATAGGTTGTACATGTACTACTTACTG3'. 4. Generation of vpr(-) mutants
  • the pCMV-HIV-1 was digested with
  • the pCMV-HIVvpr(-)nef(-) double mutant was generated by digesting the pCMV-HIVnef(-) with EcoRI and repaired with the Klenow fragment as described above.
  • pCH-GP-1 To generate pCH-GP-1, the 0.66-kb fragment between position 766 and the SphI site at position 1447 in pNL4-3 was amplified by polymerase chain reaction (PCR) using the oligonucleotides Gag5' 5'GAGGATCCTAGAAGGA- GAGAGATGGGT3' and Gag3' 5'GAGGATCCAATAGGCCCTGCATGCACTG3'. The resulting fragment was ligated with the 3.7-kb Sphl-NdeJ fragment from pNL4-3 and the 4-kb Sall-EcoRI fragment from pCMV-G.
  • PCR polymerase chain reaction
  • the RRE (between positions 7754 and 8013 in HXB-2 (33)) was amplified by PCR from pv653RSN (31) using the oligonucleotides RRE5 5'GCAAGCTTCTGCAGAGCA-GTGGGAATAGG3' and RRE3 5' GCAAGCTTAC CCCAAATCCC CAGGAGCTG 3' and cloned immediately after the gag/pol gene in pCHGP-1. This construct was designated pCH-GP-2 ( Figure 3A).
  • the 650-bp Stul-Hindlll HBV fragment spanning the PRE region (Liang & Huang, Mol Cell. Biol. 13:1416, 1993; Huang & Yen, J. Virol 65:3193, 1994; Donello et al., J. Virol 70:4345, 1996) in pCCAT-1 (Yee, Science 246:658, 1989) is inserted into the EcoRV site of pBluescript SK(-) to form pSK-PRE.
  • the PRE fragment in pSK-PRE is isolated by Clal and EcoRI digestion and cloned into the Clal and EcoRI-digested pCH-GP-1 to form pCH-GP-3 ( Figure 3B).
  • the amphotropic env or the VSV-G can be expressed instead of the HIV env to pseudotype the HIV vectors.
  • the first strategy is to establish 293 cell lines expressing the HIV tat necessary for efficient expression of the vector genomic RNA.
  • a 360-bp Sall-BamHI fragment spanning the first exon of the tat gene is isolated from pCVl (Arya et al, Science 229:69, 1985).
  • a 1390-bp Xbal-Xhol fragment containing the CMV promoter and the rabbit ⁇ -globin gene splice signal is isolated from pCMV-G.
  • a 3295-bp BamHI-Xbal fragment containing the polyadenylation site of the rabbit ⁇ -globin gene is also isolated from pCMV-G. All three fragments are ligated together to form pCMV-tat ( Figure 4A).
  • pCMV-tat To establish stable tat-expressing cell lines, 293 cells are co-transfected with pCMV-tat and pSV2-gpt (Mulligan & Berg, Proc. Natl Acad. Sci. USA 75:2072, 1981 , obtained from ATCC) at a ratio of 10 to 1. The transfected cells are subjected to selection in mycophenolic acid, xanthine and HAT-containing medium.
  • the surviving cells are pooled and clones are isolated by limiting dilution.
  • To screen for tat expression the culture supernatant from each clone is spotted on a nylon membrane and tat is detected by the ECL Western blotting system (Amersham, Arlington Heights, IL) using an anti-tat antibody (Advanced Biotechnologies Inc., Columbia, MD).
  • To express the HIV gag/pol pCH-GP-3 or pCH-GP-4 is co-transfected with pFR400 (Proc. Natl. Acad. Sci. USA 80:2495, 1983) into 293/tat cells.
  • the transfected cells are selected in methotrexate (Mtx)-containing medium and cloned by limiting dilution.
  • Mtx methotrexate
  • Mtx-resistant clones are picked and gag/pol expression is assayed by HIV p24 in culture supernatant.
  • the 293/tat/gag/pol clone expressing the highest level of p24 is expanded and used for stable expression of amphotropic env.
  • pCMVenv am DraI PCT #WO 92/05266; US patent #5,591 ,624) is co-transfected with pTK-puro (Chen et al., Proc. Natl Acad. Sci. USA 95: 10057, 1996) into the 293/tat/gag/pol cells.
  • the 293/tat/gag/pol/env clones are isolated from puromycin-resistant colonies by limiting dilution.
  • Expression of the env gene is detected by Western blot analysis using, RLV gP69/71, the anti-env polyclonal antibody (Quality Biotech Inc., Camden, NJ).
  • VSV-G The clone expressing the highest level of env is identified and expanded.
  • Packaging cell lines expressing VSV-G instead of the amphotropic env are also established.
  • the VSV-G gene is under the control of the inducible promoter of the tet system (Gossen & Bujard, Proc. Natl Acad. Sci. USA 59:5547, 1992, obtained from Bujard) in pTetO-G-2 (Chen et al, Proc. Natl. Acad. Sci. USA 95: 10057, 1996) since stable VSV-G expression resulted in cell death.
  • stable 293 clones expressing tTAER Choen et al., Proc. Natl Acad. Sci.
  • the transactivator for the inducible promoter need to be established first.
  • the 293/tat cells described above are transfected with phyg-CMV-tTAER (Chen et al., Proc. Natl. Acad. Sci. USA 95: 10057, 1996) and hygromycin-resistant clones are isolated by limiting dilution.
  • pUHC 13-3 Gossen & Bujard, Proc. Natl Acad. Sci.
  • the 293/tat/tTAER/gag/pol cells are transfected with pTetO-G-2 and selected in puromycin-containing medium.
  • the 293/tat/tTAER/gag/pol/G clone expressing low level of VSV-G is isolated by limiting dilution of the puromycin-resistant cells, followed by ⁇ -estradiol induction of VSV-G expression and FACS analysis using II , the monoclonal antibody specific for G (Burns et al., Proc. Natl. Acad. Sci. USA 90:8033, 1993).
  • Clones expressing low-level of VSV-G are isolated because high-level VSV-G expression leads to rapid cell death (within 4 to 5 days) whereas low-level VSV-G expression has little effect on cell growth, resulting in an extended duration of virus harvest ( up to two weeks) (Chen et al., Proc. Natl. Acad. Sci. USA 95: 10057, 1996).
  • the packaging cell lines described above express HIV gag and pol using the CTE and PRE sequence which bypass the requirement of rev and RRE for efficient transportation of the gag/pol mRNA from nucleus into cytoplasm.
  • 293/tat/tTAER cells are co- transfected with pCH-GP-2 and pFR400, and the transfected cells are cloned selection in Mtx-containing medium and limiting dilution. Mtx-resistant clones are picked and gag/pol expression is assayed by introducing the rev gene into these clones.
  • these clones are infected with the KT-1 virus (Chiron Technologies, San Diego, CA) containing the HIV rev gene in a MLV-based vector. HIV p24 in culture supernatant is assayed 48 hours after infection. The 293/tat/tTAER/ gag/pol clone expressing the highest level of p24 upon rev introduction will be expanded and used for stable expression of rev. Since high-level expression of rev can be toxic to cells, the rev gene is placed under the control of the inducible promoter of the tet system.
  • KT-1 virus Choiron Technologies, San Diego, CA
  • the 722-bp Bsu36I fragment containing the rev cDNA is isolated from pCVl and inserted into the unique BamHl site of pUHGlO-3 (Gossen & Bujard, Proc. Natl. Acad. Sci. USA 59:5547, 1992, obtained from Bujard) to form pTetO-rev ( Figure 4B).
  • pTetO-rev is co-transfected with pTK-phleomycin (Yee, personal communication) into 293/tat/tTAER/gag/pol cells.
  • the clone expressing the highest level of rev is identified by limiting dilution of phleomycin-resistant cells, followed by ⁇ -estradiol induction and p24 detection in the culture supernatant.
  • VSV-G or amphotropic env in 293/tat/tTAER/gag/pol/rev am cells To express VSV-G or amphotropic env in 293/tat/tTAER/gag/pol/rev am cells, the VSV-G gene in pTetO-G-2 or the amphotropic env gene in pCMVenv Dral is introduced into the 293/tat/tTAER/gag/pol/rev cells and clones expressing either
  • VSV-G or env are isolated as described above.
  • Genes encoding the accessory protein can be PCR amplified from pNL4- 3 and cloned into pCMV-Bam for expression.
  • the plasmid is co-transfected with pCMUIV-K (Song et al., J. Biol Chem. 269:7024, 1994, obtained from Per Peterson, b The Scripps Research Institute, La Jolla, CA) containing the murine H-2K cDNA into one of the packaging cell lines described above.
  • Transfected cells are isolated by FACS b sorting using Y3, the monoclonal antibody for H-2K .
  • the clone expressing the highest level of the accessory protein is identified using Western blot analysis with the specific polyclonal antibody (obtained from NIH AIDS Reagent Program).
  • the PCR amplified Vpr cDNA is inserted into pUHGlO-3 under the control of the tet inducible promoter as described for the rev expression.
  • the construct is co-transfected with pCMUIV- K b into the packaging cell lines and the Vpr- expressing clone is isolated as described above.
  • cf2 and D17-based packaging cell lines are established to test viral titer potential with the same strategy described above.
  • the HIV vector described above is co- transfected with pCMV-G and pCMV ⁇ R9 (Naldini et al., Science 272:263, obtained from Verma, The Salk Institute, La Jolla, CA) into 293 cells.
  • VCL clones are isolated by the neo selection or FACS sorting with the antibody specific for the marker gene carried in the vector ( ⁇ -gal, alkaline phosphatase or nerve growth factor receptor). Titer potential for the clones is determined by infecting HT1080 cells with the harvested virus from each clone, followed by the neo selection or FACS analysis.
  • 5 x 10 4 HT1080 cells were plated in a 12- well plate in the presence of 8 ⁇ g/ml polybrene 24 hours prior to infection. The cells were infected overnight with various dilutions of the vector and assayed for the b-gal activity 48 hours after infection.
  • Results are shown in Figure 7. Briefly, as can be seen by this table, deletion of the accessory protein from the vector particle appears to have little effect on vector titer.
  • Results of the five plasmid transfection protocol are shown in Figure 9. Briefly, as noted above, utilizing the five-plasmid transfection protocol all accessory proteins can be eliminated. Moreover, the possibility of generating replication competent virus is greatly reduced.
  • HeLa cells were exposed to gamma- irradiation to anest cells at the G2 phase of the cell cycle. More specifically, proliferating or growth-anested HeLa cells were transduced with either MLV- ⁇ -gal, a ⁇ -gal gene-containing MLV vector or the HIV- 1 -based vector v653CMV ⁇ -gal(+) containing all four accessory proteins or v653CMVb-gal(-) containing no accessory protein. Positive cells were scored by X-Gal staining two days after transduction.
  • results in HeLa were expressed as the percentage of titers observed with the same virus preparations in growing HT1080. As shown in Figure 10, no significant difference in titer was observed in proliferating or quiescent HeLa cells transduced with either the v653CMV ⁇ -gal(+) or the v653CMV ⁇ -gal(-) vector. In contrast, the transduction efficiency of the MLV vector in quiescent cells was reduced more than 2000 fold. Similar results were obtained with inadiated HT1080 cells, transduced with the three vectors (data not shown).
  • v653CMV ⁇ -gal(-) defective for the HIV-1 accessory proteins showed a 4- to 7 fold decreased level of efficiency to transduce the contact- inhibited fibroblasts relative to the v653CMV ⁇ -gal(+) vector.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des vecteurs lentiviraux comprenant une longue répétition terminale (LTR) lentivirale 5', un site de fixation d'ARNt, un signal d'encapsidation, un promoteur fixé de manière fonctionnelle à un ou à plusieurs gènes d'intérêt, une origine de la synthèse du second brin d'ADN et une LTR lentivirale 3', le vecteur lentiviral contenant un élément de transport nucléaire qui n'est pas RRE (site de liaison de la protéine Rex). L'invention concerne également des cassettes d'expression et des lignées de cellules d'encapsidation permettant de produire des particules de vecteurs lentiviraux.
PCT/US1998/014996 1997-07-18 1998-07-20 Vecteurs lentiviraux WO1999004026A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU85762/98A AU8576298A (en) 1997-07-18 1998-07-20 Lentiviral vectors
EP98936923A EP1003894A2 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux
JP2000503232A JP2001510053A (ja) 1997-07-18 1998-07-20 レンチウイルスベクター
CA002296319A CA2296319A1 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5306697P 1997-07-18 1997-07-18
US60/053,066 1997-07-18

Publications (2)

Publication Number Publication Date
WO1999004026A2 true WO1999004026A2 (fr) 1999-01-28
WO1999004026A3 WO1999004026A3 (fr) 1999-04-08

Family

ID=21981716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014996 WO1999004026A2 (fr) 1997-07-18 1998-07-20 Vecteurs lentiviraux

Country Status (5)

Country Link
EP (1) EP1003894A2 (fr)
JP (1) JP2001510053A (fr)
AU (1) AU8576298A (fr)
CA (1) CA2296319A1 (fr)
WO (1) WO1999004026A2 (fr)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999036511A2 (fr) * 1998-01-16 1999-07-22 Chiron Corporation Vecteurs de therapie genique du virus de l'immunodeficience feline
WO2000000600A2 (fr) * 1997-09-22 2000-01-06 Chang Lung Ji Vecteurs lentiviraux
WO2000006760A1 (fr) * 1998-07-29 2000-02-10 The Government Of The United States Of America, R Epresented By The Secretary, Department Of Health And Human Services Utilisation d'elements de transport constitutifs pour le control de la gamme d'hote
EP1037669A1 (fr) * 1997-12-12 2000-09-27 Luigi Naldini Emploi therapeutique de vecteurs lentiviraux
WO2000065034A2 (fr) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotype de vecteur retroviral destine a la therapie genique du cancer
WO2000075351A1 (fr) * 1999-06-09 2000-12-14 Syngenix Limited Vecteurs a encapsidation deficiente bases sur le siv
WO2001089580A1 (fr) * 2000-05-22 2001-11-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Transduction systemique et cardiovasculaire associee a des vecteurs lentiviraux
WO2001092506A1 (fr) * 2000-05-30 2001-12-06 University Of Rochester Systemes de vecteurs lentiviraux derives de virus d'immunodeficience simienne (siv)
EP1171624A1 (fr) * 1999-04-29 2002-01-16 Cell Genesys, Inc. Procede et moyens de production de vecteurs lentiviraux recombinants surs et a titre eleve
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
US6730297B1 (en) * 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
US6924144B2 (en) 1997-12-12 2005-08-02 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7198950B2 (en) 2001-10-02 2007-04-03 Institut Clayton De La Recherche Methods and compositions relating to restricted expression lentiviral vectors and their applications
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP2055316A1 (fr) * 2003-09-09 2009-05-06 VIRxSYS Corporation Approches basées sur un vecteur lentivirus pour la génération d'une réponse immunitaire au VIH chez les humains
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US7582614B2 (en) 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7629153B2 (en) 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8043612B2 (en) 1997-10-09 2011-10-25 Wellstat Biologics Corporation Infection and treatment of neoplasms with vesicular stomatitis virus
EP2388315A2 (fr) 2005-03-07 2011-11-23 Robarts Research Institute Utilisation d'une combinaison de virus du myxome et rapamycine pour traitement thérapeutique
US8105578B2 (en) 1997-10-09 2012-01-31 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US8623382B2 (en) 2004-06-17 2014-01-07 Wyeth Llc Immunogenic compositions for inducing an immune response to HIV
CN107949424A (zh) * 2015-03-20 2018-04-20 天普大学-联邦高等教育系统 Tat诱导的基于crispr/核酸内切酶的基因编辑
CN113166782A (zh) * 2018-09-20 2021-07-23 国立大学法人东京医科齿科大学 增强慢病毒载体产生的方法
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
US12258574B2 (en) 2016-03-19 2025-03-25 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031923A1 (fr) 2014-12-11 2016-06-15 Institut Pasteur Composition immunogène contre l'encéphalite japonaise à base de vecteurs lentiviraux
US20180094280A1 (en) * 2015-03-20 2018-04-05 Bluebird Bio, Inc. Vector formulations
US20210361775A1 (en) * 2018-05-18 2021-11-25 Zhengzhou Gensciences Inc Improved fviii fusion protein and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031602A1 (fr) * 1995-04-01 1996-10-10 Oxford Biomedica (Uk) Limited Vecteurs retroviraux
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
WO1997012622A1 (fr) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division
WO1997020052A1 (fr) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
WO1996031602A1 (fr) * 1995-04-01 1996-10-10 Oxford Biomedica (Uk) Limited Vecteurs retroviraux
WO1997012622A1 (fr) * 1995-10-06 1997-04-10 The Salk Institute For Biological Studies Vecteur et procede permettant d'alimenter en acide nucleique des cellules ne subissant pas de division
WO1997020052A1 (fr) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Vih recombine, cellules d'encapsidation modifiees et methode de traitement du syndrome d'immunodeficience acquise

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENDER M. A. ET AL.: "EVIDENCE THAT THE PACKAGING SIGNAL OF MOLONEY MURINE LEUKEMIA VIRUS EXTENDS INTO THE GAG REGION" JOURNAL OF VIROLOGY, vol. 61, no. 5, 19 May 1987, pages 1639-1646, XP002036903 *
BRAY M. ET AL. : "A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type I expression and replication Rev-independent." PROC. NATL. ACAD. SCI. USA, vol. 91, 1994 - 1256, page 1260 XP002092484 cited in the application *
HUANG J. AND LIANG T. J.: "A novel hepatitis B virus (HBV) genetic element with Rev response element-like properties that is essential for expression of HBV gene products." MOLECULAR AND CELLULAR BIOLOGY, vol. 13, no. 12, 1993, pages 7476-7486, XP000676652 cited in the application *
LEVINE F. ET AL.: "Efficient gene expression in mammalian cells from a dicistronic transcriptional unit in an improved retroviral vector." GENE, vol. 108, 1991, pages 167-174, XP002092486 cited in the application *
MORGAN R. A. ET AL: "RETROVIRAL VECTORS CONTAINING PUTATIVE INTERNAL RIBOSOME ENTRY SITES: DEVELOPMENT OF A POLYCISTRONIC GENE TRANSFER SYSTEM AND APPLICATIONS TO HUMAN GENE THERAPY" NUCLEIC ACIDS RESEARCH, vol. 20, no. 6, 1992, pages 1293-1299, XP002037514 *
NALDINI L. ET AL.: "IN VIVO GENE DELIVERY AND STABLE TRANSDUCTION OF NONDIVIDING CELLS BY A LENTIVIRAL VECTOR" SCIENCE, vol. 272, no. 5259, 12 April 1996, pages 263-267, XP000583652 *
ORY D. S. ET AL.: "A STABLE HUMAN-DERIVED PACKAGING CELL LINE FOR PRODUCTION OF HIGH TITER RETROVIRUS/VESICULAR STOMATITIS VIRUS G PSEUDOTYPES" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, October 1996, pages 11400-11406, XP002030784 *
SRINIVASAKUMAR N. ET AL.: "The effect of viral regulatory protein expression on gene delivery by human immundeficiency virus type I vectors produced in stable packaging cell lines." JOURNAL OF VIROLOGY, vol. 71, no. 8, August 1997, pages 5841-5848, XP002092487 *

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO2000000600A2 (fr) * 1997-09-22 2000-01-06 Chang Lung Ji Vecteurs lentiviraux
WO2000000600A3 (fr) * 1997-09-22 2000-10-12 Chang Lung Ji Vecteurs lentiviraux
US8105578B2 (en) 1997-10-09 2012-01-31 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8043612B2 (en) 1997-10-09 2011-10-25 Wellstat Biologics Corporation Infection and treatment of neoplasms with vesicular stomatitis virus
EP1037669A1 (fr) * 1997-12-12 2000-09-27 Luigi Naldini Emploi therapeutique de vecteurs lentiviraux
US8846385B2 (en) 1997-12-12 2014-09-30 Gbp Ip, Llc Method and means for producing high titer, safe recombinant lentivirus vectors
US6924144B2 (en) 1997-12-12 2005-08-02 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1037669A4 (fr) * 1997-12-12 2003-04-02 Cell Genesys Inc Emploi therapeutique de vecteurs lentiviraux
US7083981B2 (en) 1997-12-12 2006-08-01 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999036511A2 (fr) * 1998-01-16 1999-07-22 Chiron Corporation Vecteurs de therapie genique du virus de l'immunodeficience feline
WO1999036511A3 (fr) * 1998-01-16 1999-09-16 Chiron Corp Vecteurs de therapie genique du virus de l'immunodeficience feline
US6492166B1 (en) 1998-07-29 2002-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of constitutive transport elements for host range control
WO2000006760A1 (fr) * 1998-07-29 2000-02-10 The Government Of The United States Of America, R Epresented By The Secretary, Department Of Health And Human Services Utilisation d'elements de transport constitutifs pour le control de la gamme d'hote
WO2000065034A3 (fr) * 1999-04-23 2001-01-25 Ct For Translational Res In Ca Pseudotype de vecteur retroviral destine a la therapie genique du cancer
WO2000065034A2 (fr) * 1999-04-23 2000-11-02 Centre For Translational Research In Cancer Pseudotype de vecteur retroviral destine a la therapie genique du cancer
US8652837B2 (en) 1999-04-29 2014-02-18 Gbp Ip, Llc Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1849873A1 (fr) * 1999-04-29 2007-10-31 Cell Genesys, Inc. Procédé et supports de production de vecteurs de lentivirus recombinant sécurisé à fort dosage
EP1171624A4 (fr) * 1999-04-29 2002-06-26 Cell Genesys Inc Procede et moyens de production de vecteurs lentiviraux recombinants surs et a titre eleve
EP1171624A1 (fr) * 1999-04-29 2002-01-16 Cell Genesys, Inc. Procede et moyens de production de vecteurs lentiviraux recombinants surs et a titre eleve
JP4979851B2 (ja) * 1999-04-29 2012-07-18 ジービーピー アイピー リミテッド ライアビリティ カンパニー 高いタイターで安全な組換えレンチウイルスベクターの作製方法
US7250299B1 (en) 1999-04-29 2007-07-31 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6730297B1 (en) * 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
US7034010B2 (en) 1999-05-28 2006-04-25 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
WO2000075351A1 (fr) * 1999-06-09 2000-12-14 Syngenix Limited Vecteurs a encapsidation deficiente bases sur le siv
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US8076100B2 (en) 1999-12-23 2011-12-13 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
WO2001089580A1 (fr) * 2000-05-22 2001-11-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Transduction systemique et cardiovasculaire associee a des vecteurs lentiviraux
WO2001092506A1 (fr) * 2000-05-30 2001-12-06 University Of Rochester Systemes de vecteurs lentiviraux derives de virus d'immunodeficience simienne (siv)
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US8551773B2 (en) 2000-11-13 2013-10-08 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US9023646B2 (en) 2000-11-13 2015-05-05 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US10226538B2 (en) 2000-11-13 2019-03-12 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US9731033B2 (en) 2000-11-13 2017-08-15 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US8329462B2 (en) 2000-11-13 2012-12-11 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US9476062B2 (en) 2000-11-13 2016-10-25 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
US7745179B2 (en) 2001-05-14 2010-06-29 Gbp Ip, Llc Lentiviral vectors featuring liver specific transcriptional enhancer and methods of using same
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
US7179903B2 (en) 2001-05-14 2007-02-20 Cell Genesys, Inc Liver specific transcriptional enhancer
US9260725B2 (en) 2001-08-02 2016-02-16 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
US7629153B2 (en) 2001-08-02 2009-12-08 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
US8900858B2 (en) 2001-08-02 2014-12-02 Research Development Foundation Methods and compositions relating to improved lentiviral vector production systems
US7198950B2 (en) 2001-10-02 2007-04-03 Institut Clayton De La Recherche Methods and compositions relating to restricted expression lentiviral vectors and their applications
US9340798B2 (en) 2001-10-02 2016-05-17 Research Development Foundation Methods and compositions relating to restricted expression lentiviral vectors and their applications
US8748169B2 (en) 2001-10-02 2014-06-10 Research Development Foundation Methods and compositions relating to restricted expression lentiviral vectors and their applications
US8227440B2 (en) 2003-03-07 2012-07-24 Robarts Research Institute Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7582614B2 (en) 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
EP2055316A1 (fr) * 2003-09-09 2009-05-06 VIRxSYS Corporation Approches basées sur un vecteur lentivirus pour la génération d'une réponse immunitaire au VIH chez les humains
US8623382B2 (en) 2004-06-17 2014-01-07 Wyeth Llc Immunogenic compositions for inducing an immune response to HIV
EP2388315A2 (fr) 2005-03-07 2011-11-23 Robarts Research Institute Utilisation d'une combinaison de virus du myxome et rapamycine pour traitement thérapeutique
CN107949424A (zh) * 2015-03-20 2018-04-20 天普大学-联邦高等教育系统 Tat诱导的基于crispr/核酸内切酶的基因编辑
EP3271021A4 (fr) * 2015-03-20 2019-02-13 Temple University Of The Commonwealth System Of Higher Education Édition génique basée sur le système crispr/endonucléase à induction par tat
US12258574B2 (en) 2016-03-19 2025-03-25 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11597917B2 (en) 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
US12239693B2 (en) 2018-04-27 2025-03-04 The Medical College Of Wisconsin, Inc. Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders
CN113166782A (zh) * 2018-09-20 2021-07-23 国立大学法人东京医科齿科大学 增强慢病毒载体产生的方法

Also Published As

Publication number Publication date
AU8576298A (en) 1999-02-10
JP2001510053A (ja) 2001-07-31
CA2296319A1 (fr) 1999-01-28
WO1999004026A3 (fr) 1999-04-08
EP1003894A2 (fr) 2000-05-31

Similar Documents

Publication Publication Date Title
WO1999004026A2 (fr) Vecteurs lentiviraux
EP1045921A2 (fr) Vecteurs de therapie genique du virus de l'immunodeficience feline
CA2523216C (fr) Vecteurs d'alphavirus recombinant
US5997859A (en) Method for treating a metastatic carcinoma using a conditionally lethal gene
EP0830455A1 (fr) Integration de vecteurs de recombinaison dans une position specifique du genome d'un eucaryote, assuree par une proteine chimere du type integrase
ES2627445T3 (es) Partículas de vector de lentivirus resistentes a la inactivación por el complemento
WO1998000541A9 (fr) Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
EP0951544A2 (fr) Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
EP0800403A2 (fr) Administration atraumatique de vehicules d'apport de genes
WO1996020732A9 (fr) Administration atraumatique de vehicules d'apport de genes
US20030003565A1 (en) Functional lentiviral vector from an MLV-based backbone
US5932467A (en) Retroviral vectors pseudotyped with SRV-3 envelope glycoprotein sequences
WO2005116225A1 (fr) Methode d'introduction et d'expression d'arn dans des cellules
WO2002002789A2 (fr) Compositions et procedes permettant de fabriquer des virions de recombinaison
WO1996021014A2 (fr) Production et administration de retrovirus recombines a titre eleve
EP0917585A2 (fr) Vecteurs d'administration d'inhibiteurs de cellules virales et oncogenes
US20040063652A1 (en) Combination gene delivery vehicles
JPH11504802A (ja) 組換えアルファウイルスベクター
US20060121011A1 (en) Combination gene delivery vehicles
JPH10511951A (ja) 高力価組換えレトロウイルスの産生および投与

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2296319

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2296319

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1998936923

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 85762/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998936923

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998936923

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载